Synthetic vaccines against porphyromonas gingivalis

Abstract

The present invention relates to a synthetic saccharide of general formula (I) that is related to Porphyromonas gingivalis lipopolysaccharide specifically the O-antigen, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Porphyromonas gingivalis bacteria. Another aspect of the present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I).

Description

[0001] 1 Synthetic vaccines against Porphyromonas gingivalis Field of the invention 5 The present invention relates to a synthetic saccharide of general formula (I) that is related to Porphyromonas gingivalis lipopolysaccharide specifically the O-antigen, aconjugate thereof and the use of said saccharide and conjugate for raising a protectiveimmune response in a human and / or animal host. Furthermore, the synthetic10 saccharide of general formula (I) is useful as marker in immunological assays fordetection of antibodies against Porphyromonas gingivalis bacteria. Another aspect ofthe present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I). 15 Background of the invention Porphyromonas gingivalis (P. gingivalis) is a Gram-negative, anaerobic, rod-shaped bacterium, that colonizes the oral epithelium and is an important component of 20 subgingival microbiomes (Mei et al., Pathogens 2020, 9, 944). Besides Tannerella forsythia and Treponema denticola, it is part of the so called “red complex” thatincludes the main pathogens in the development of chronic periodontitis (CP). Studies have demonstrated that P. gingivalis strains vary in their virulence, with somestrains being classified as virulent, e.g. strains W50, ATCC 49417 and A7A1 and 25 others being classified as avirulent, e.g. strains 381, 33277 and 23A4. W50 is worldwide the most common type of P. gingivalis (Igboin et al., J. Clin. Microbiol.2009, 47, 3073-3081). Among surface components of the bacterial envelope, polysaccharides such as the 30 K-antigen (capsule) and the lipopolysaccharide (LPS) are essential for virulence and immunogenicity of P. gingivalis. The main virulence factors include its own structuralcomponents (lipopolysaccharide (LPS), fimbriae, heat shock proteins) and secretory components (gingipains and outer membrane vesicles).35 Outer membrane vesicles of P. gingivalis are enriched in many virulence factorsincluding the LPS and proteins such as well-studied gingipains and the peptidyl- arginine deiminase (PPAD). Outer membrane vesicles participate in biofilm development, host interaction, colonization and immune defense evasion. They are double-layer spherical membrane-like structures with a diameter of about 50-250 nm

[0002] GAR-P04580WO13 Application (final).docx 2 and due to their size, they can easily penetrate deep tissues compared to the parent bacterium. They are released into the hosts tissue and can be internalized into host- cells (Gui et al. Mol. Oral Microbiol.2016, 31, 365-378).5 The peptidoglycan layer of the gram-negative bacterium P. gingivalis is surroundedby an outer membrane that contain, among others, lipopolysaccharides (LPS)organized in vesicles. Those outer membrane vesicles can be internalized into host cells. After lysis of the outer membrane vesicle, various antigens from the outer membrane and the underlying periplasm may be processed by antigen-presenting10 cells leading to the induction of an adaptive immune response including P. gingivalis- specific antibody production. The LPS is the major component of the outer bacterial membrane. It is a complex glycolipid that is composed of three covalently linked domains: The lipid A or 15 endotoxin, the central oligosaccharide core and the O-antigen, which is the most external part of this molecule (Raetz et al. Annu. Rev. Biochem. 2002, 71, 635-700).The glycan part in the O-antigen (O-LPS) of P. gingivalis W50 is built up of the tetrasaccharide repeating sequence [→6)-α-D-Glcp-(1→4)-α-L-Rhap-(1→3)-β-D- GalNAc- (1→3)-α-D-Galp-(1→] and bears a monophosphoethanolamine residue at20 position C2 of the α-rhamnose in a nonstoichiometric (approximately 60%) amount (see Figure 1). The LPS of P. gingivalis is a significant antigen in periodontitis patients, which offers opportunities for the development of a carbohydrate-based conjugate vaccine. 25 Periodontal diseases are very prevalent and constitute a major public health problem. According to the World Health Organization, 10-15% of adults worldwide suffer from severe periodontal diseases. Regarding the described connection to systemicdiseases, periodontal disease has immense social impact and poses a huge challenge towards global health care. Since P. gingivalis is the major cause for30 periodontal diseases, it is an important target in research on systemic diseases. Therefore, a significant amount of research and extensive analysis of P. gingivalisover the past decades resulted in evidences of its role in atherosclerosis, Alzheimer’s disease, rheumatoid arthritis, cancer, diabetes, and adverse pregnancy outcomes.The ability of P. gingivalis to travel to distant sites might participate in P. gingivalis- 35 associated systemic disorder. P. gingivalis in local periodontal tissue can enter the vasculature through ulcerated epithelium and lymph vessels by brushing and chewing. This was indicated by the detection of P. gingivalis in synovial fluid and plasma as well as by isolation of P. gingivalis from human atherosclerotic plaquetissues, mouse lungs, human Alzheimer’s brains, aortic endothelial cells, pancreatic

[0003] GAR-P04580WO13 Application (final).docx 3 tumor cells, and human myeloid dendritic cells. Periodontal bacteria also have beenfound in cardiovascular disease plaques and the detection rate of P. gingivalis has been 100%. 5 Alzheimer’s disease (AD), the most common type of dementia, is a chronic neurodegenerative disease where patients suffer from progressive memory loss, disorientation, and cognitive performance deficits. The number of dementia cases isprojected to reach more than 140 million by 2050 and thus AD is a major challenge for global health and social care. Until now, the current understanding of AD 10 pathogenesis is limited, which hinders efficient treatment and prevention. However, epidemiological studies, animal experiments and other evidence have strengthenedsupport for the possible relevance of P. gingivalis in AD pathogenesis. For example, DNA, LPS and gingipains of P. gingivalis have been identified in AD brains and oral P. gingivalis infection in mice resulted in an increased production of amyloid-β1-4215 (Aβ1-42) plaques. The pathology of AD is based on Aβ plaques, neurofibrillary tangles and microglia-mediated neuroinflammation. Studies suggest that infection with P. gingivalis can lead to direct disruption of the blood-brain barrier, or bacteria find leaky regions lacking of blood-brain barrier, invade peripheric nerves or invade immune cells followed by brain recruitment and finally enter into the brain causing 20 neuroinflammation. In addition to the direct role of P. gingivalis, the release of inflammatory molecules from infected host cells, such as a set of cytokines and their immune response may also be involved in AD pathogenesis. Another theory is the suppression of the host’s adaptive immune system, which could allow P. gingivalis to prevent the entry of immune cells into the brain, or an increased blood-brain barrier25 permeability, or the inhibition of the local IFN-γ response.]The current CP control measures heavily rely on the mechanical removal of dental plaque, which disrupts the disease-triggering dysbiotic biofilm. This includes toothbrushing, interdental cleaning, frequent professional dental cleaning, but also 30 pocket reduction surgery, regenerative surgery, laser therapy and local or systemic antimicrobials. Broecker et al. ("Generation of Monoclonal Antibodies against Defined Oligosaccharide Antigens: Methods and Protocols" In: "Carbohydrate-Based 35 Vaccines: Methods and Protocols” 2015) report on a method for producing highly affine monoclonal antibodies (mAbs) against well-defined synthetic carbohydrate antigens. The method involves conjugating an oligosaccharide to an immunogenic carrier protein to create a glycoconjugate, which is then used for immunization in mice. Splenocytes from immunized mice are fused with myeloma cells to generate

[0004] GAR-P04580WO13 Application (final).docx 4 hybridomas, which are screened using glycan microarrays to identify clones producing specific mAbs. Selected hybridomas are expanded, and the antibodies are purified from the culture supernatant. This method enables the efficient production of carbohydrate-specific mAbs with high specificity, selectivity, and affinity, making them 5 valuable for diverse biochemical and medical applications. Chakkumkal Anish et al. ("Chemical Biology Approaches to Designing Defined Carbohydrate Vaccines", Chemistry & Biology, vol.21, no.1, 1 January 2014 (2014- 01-01), pages 38-50) review key innovations driving carbohydrate-based vaccine 10 development and cutting-edge technologies that support these efforts. A rational design approach, leveraging structurally defined and fully synthetic oligosaccharides informed by molecular insights into antigen-antibody interactions, holds significant potential for the next generation of carbohydrate vaccines. 15 Paramonov et al: ("Structural analysis of the polysaccharide from the lipopolysaccharide of Porphyromonas gingivalis strain W50", European Journal of Biochemistry, vol. 268, no. 17, 1 September 2001 (2001-09-01), pages 4698-4707) characterized the structure of the O-polysaccharide from P. gingivalis strain W50using comprehensive1D and2D NMR spectroscopy along with GC-MS analysis. The 20 authors could demonstrate that the O-polysaccharide consists of a repeating tetrasaccharide unit with the sequence: →6)-α-D-Glcp-(1→4)-α-L-Rhap-(1→3)-β-D- GalNAc-(1→3)-α-D-Galp-(1→. An additional monophosphoethanolamine modification at the C-2 position of the α-rhamnose residue in approximately 60% of the molecules could be identified. 25 Many researchers try to explore whether controlling P. gingivalis can be a potential treatment of systemic diseases. Proposed approaches include broad-spectrum antibiotics and specific inhibitors. Doxycycline and metronidazole resulted in significant reduction in atherosclerotic lesions in mice. Small molecule gingipain30 inhibitors have been found to block gingipain-induced neurodegeneration, suggesting that it could be used to treat P. gingivalis brain colonization and neurodegeneration in AD. However, pre-immunization could reduce the ability of the bacteria to translocate to remote tissues. For a successful periodontal vaccine, immunity in the oral cavity 35 should be induced, which is difficult with traditional vaccination methods. Advances in mucosal vaccination strategies might give the option for periodontal disease control. The intranasal route is a major mucosal route and the nasal influenza vaccine was the pioneering application in humans. Sublingual immunization with a recombinant vaccine that contains P. gingivalis heat shock protein 60 or nasal immunization with

[0005] GAR-P04580WO13 Application (final).docx 5 outer membrane vesicles prior to P. gingivalis injection significantly reduced arteriosclerotic lesion in mice (Koizumi et al. Infect. Immun. 2008, 76, 2958-2965;Hagiwara et al. J. Dent. Res.2014, 93, 382-387). The nasal immunization with outer membrane vesicles in mice resulted in the detection of a significant increase in P. 5 gingivalis specific IgA in the nasal lavage fluid and saliva of mice, as well as serum IgG and IgA. In view of the encouraging results, it is of high interest to provide noveltherapeutic strategies for systemic diseases caused by P. gingivalis.It is the objective of the present invention to provide a saccharide of general formula (I)10 that is related to the Porphyromonas gingivalis lipopolysaccharide, specifically theO-antigen, as well as a conjugate of the saccharide of general formula (I) with an immunogenic carrier, such as a carrier protein, as well as an antibody having specificity for the saccharide of general formula (I). The saccharide of general formula (I), and particularly the conjugate of said saccharide with an immunogenic carrier is able to15 raise a protective immune response against P. gingivalis LPS O-antigen in a humanand / or animal host. Thus, a vaccine composition for immunization against P. gingivaliscomprising the saccharide of general formula (I), and / or a conjugate thereof is provided. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against P. gingivalis bacteria.20 The objective of the present invention is solved by the teaching of the independent claims. Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, the figures, and the examples of the present application. 25 Description of the invention Definitions 30 The term “linker” as used herein encompasses molecular fragments capable of connecting the reducing-end monosaccharide of a saccharide with an immunogenic carrier or a solid support, optionally by binding to at least one interconnecting molecule. Thus, the function of the linker per se or together with the interconnectingmolecule is to establish, keep and / or bridge a special distance between the reducing- 35 end monosaccharide and an immunogenic carrier or a solid support. More specifically, one extremity of the linker is connected to the exocyclic oxygen atom at the anomeric center of the reducing-end monosaccharide and the other extremity is connected via the nitrogen atom with the interconnecting molecule, or directly withthe immunogenic carrier or the solid support.

[0006] GAR-P04580WO13 Application (final).docx 6 As used herein, the term “interconnecting molecule” refers to a bifunctional molecule containing functional group X and functional group Y, wherein functional group X is capable of reacting with the terminal amino group on the linker L and the functional 5 group Y is capable of reacting with a functionality present on an immunogenic carrier or on a solid support. Figure 2 displays examples of commercially availableinterconnecting molecules, but does not restrict the interconnecting molecules that can be used according to the present invention to the examples displayed herein. 10 The term “adjuvant” as used herein refers to an immunological adjuvant i.e. a material used in a vaccine composition that modifies or augments the effects of said vaccine by enhancing the immune response to a given antigen contained in the vaccine without being antigenically related to it. For the person skilled in the art, classically recognized examples of adjuvants include:15 - mineral-containing compositions, including calcium salts and aluminium salts(or mixtures thereof). Calcium salts include calcium phosphate. Aluminium salts include hydroxides, phosphates, sulfates, etc., with the salts taking any suitable form (e.g. gel, crystalline, amorphous, etc.). Adsorption to these salts is preferred. The mineral containing compositions may also be formulated as a particle of metal salt. 20 The adjuvants known as aluminium hydroxide and aluminium phosphate may be also used. The invention can use any of the "hydroxide" or "phosphate" adjuvants that are in general used as adjuvants. The adjuvants known as "aluminium hydroxide" are typically aluminium oxyhydroxide salts, which are usually at least partially crystalline. The adjuvants known as "aluminium phosphate" are typically aluminium 25 hydroxyphosphates, often also containing a small amount of sulfate (i. e. aluminium hydroxyphosphate sulfate). They may be obtained by precipitation, and the reaction conditions and concentrations during precipitation influence the degree of substitution of phosphate for hydroxyl in the salt. Mixtures of both an aluminium hydroxide and an aluminium phosphate can be employed in the formulation according to the present30 invention; -saponins, which are a heterologous group of sterol glycosides andtriterpenoid glycosides that are found in the bark, leaves, stems, roots and even flowers of a wide range of plant species. Saponins from the bark of the Quillaia saponaria, Molina tree have been widely studied as adjuvants. Saponins can also be 35 commercially obtained from Smilax ornata (sarsaprilla), Gypsophilla paniculata (brides veil), and Saponaria oficianalis (soap root). Saponin adjuvant formulations include purified formulations, such as QS21, as well as lipid formulations, such as ISCOMs. Saponin compositions have been purified using HPLC and RP-HPLC. Specific purified fractions using these techniques have been identified, including

[0007] GAR-P04580WO13 Application (final).docx 7 QS7, QS 17, QS 18, QS21, QH-A, QH-B and QH-C. Saponin formulations may also comprise a sterol, such as cholesterol. Combinations of saponins and cholesterols can be used to form unique particles called immunostimulating complexes (ISCOMs). ISCOMs generally include a phospholipid such as phosphatidylethanolamine or 5 phosphatidylcholine. Any known saponin can be used in ISCOMs. Preferably, the ISCOM includes one or more of QuilA, QHA & QHC; -microparticles (i.e. a particle of 100 nm to 150 pm in diameter, morepreferably 200 nm to 30 pm in diameter, or 500 nm to 10 pm in diameter) formed from materials that are biodegradable and non-toxic. Such non-toxic and 10 biodegradable materials include, but are not restricted to poly(α-hydroxy acid), polyhydroxybutyric acid, polyorthoester, polyanhydride, polycaprolactone; -CD1d ligands, such as an α-glycosylceramide, phytosphingosine-containing^-glycosylceramides, OCH, KRN7000 [(2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-(N- hexacosanoylamino)-1,3,4-octadecanetriol], CRONY- 101, 3"-sulfo-galactosyl-15 ceramide; -immunostimulatory oligonucleotides, such CpG motif containing ones (adinucleotide sequence containing an unmethylated cytosine residue linked by a phosphate bond to a guanosine residue), or CpI motif containing ones (a dinucleotide sequence containing cytosine linked to inosine), or a double-stranded RNA, or an 20 oligonucleotide containing a palindromic sequence, or an oligonucleotide containing a poly(dG) sequence. Immunostimulatory oligonucleotides can include nucleotide modifications / analogs such as phosphorothioate modifications and can be double- stranded or (except for RNA) single-stranded; -compounds containing lipids linked to a phosphate-containing acyclic25 backbone, such as the TLR4 antagonist E5564; -oil emulsions (e.g. Freund´s adjuvant).Theoretically, each molecule or substance that is able to favor or amplify a particular situation in the cascade of immunological events, ultimately leading to a more30 pronounced immunological response, can be defined as an adjuvant. In principle, through the use of adjuvants in vaccine formulations, one can -direct and optimize immune responses that are appropriate or desirable forthe vaccine; -enable mucosal delivery of vaccines, i.e. administration that results in contact35 of the vaccine with a mucosal surface such as buccal or gastric or lung epithelium and the associated lymphoid tissue; -promote cell-mediated immune responses;- enhance the immunogenicity of weaker immunogens, such as highly purifiedor recombinant antigens;

[0008] GAR-P04580WO13 Application (final).docx 8 -reduce the amount of antigen or the frequency of immunization required toprovide protective immunity; and -improve the efficacy of vaccines in individuals with reduced or weakenedimmune responses, such as newborns, the aged, and immunocompromised vaccine 5 recipients. Although little is known about their mode of action, it is currently believed that adjuvants augment immune responses by one of the following mechanisms: -increasing the biological or immunologic half-life of antigens;- improving antigen delivery to antigen-presenting cells (APCs), as well as10 antigen processing and presentation by the APCs e.g., by enabling antigen to cross endosomal membranes into the cytosol after ingestion of antigen-adjuvant complexes by APC; -mimicking danger inducing signals from stressed or damaged cells, whichserve to initiate an immune response;15 - inducing the production of immunomodulatory cytokines;- biasing the immune response towards a specific subset of the immunesystem; and -blocking the rapid dispersal of the antigen challenge.20 Saccharides are known by the person skilled in the art as TI-2 (T cell independent-2) antigens and poor immunogens. Therefore, to produce a saccharide-based vaccine, said saccharide is conjugated to an immunogenic carrier to provide a conjugate,which presents an increased immunogenicity in comparison with the saccharide. In this context the term “immunogenic carrier” is defined as a structure, which is 25 conjugated to the saccharide to form a conjugate that presents an increased immunogenicity in comparison with the saccharide per se. Thus, the conjugation ofthe saccharides to the immunogenic carrier has as effect the stimulation of the immune response against said saccharide, without inducing an immune response against the said immunogenic carrier. 30 Surprisingly, it was found that a pure saccharide of general formula (I) according tothe present invention contains a protective immunogenic glycan epitope and is able to induce a protective immune response against Porphyromonas gingivalis bacteriain a human and / or animal host. The saccharide of general formula (I) elicits35 antibodies that are cross-reacting with the P. gingivalis lipopolysaccharide, recognizespecifically P. gingivalis bacteria.

[0009] GAR-P04580WO13 Application (final).docx 9 Thus, the present invention relates to a saccharide of general formula (I) H–Ux+2–Ux+1–Ux–T–O–L–NH2(I) 5 wherein x is an integer selected from 1 and 3; 10 –T– represents a bond, –Ux+3–, –Ux+3–Ux+2–, –Ux+3–Ux+2–Ux+1–, or –[Ux+3–Ux+2–Ux+1–Ux]n– with n being an integer selected from 1, 2 and 3;R1represents –H or –PO2–O–CH2CH2–NH2; L represents a linker; or a pharmaceutically acceptable salt thereof15 –L– is defined as a linker and is part of the fragment –O–L–NH2. Thus, the linker–L– is bound to an oxygen atom and to the nitrogen atom of the NH2-group. It ispreferred that at least two carbon atoms of the linker are between the oxygen atom and the NH2-group, like –O–C–C–NH2. The linker –L– can be an aliphatic chain,wherein the aliphatic chain can optionally include an aromatic chain inserted in it, or a20 number of heteroatoms oscillating from 0 to 10. The linker L preferably contains between 2 and 40 carbon atoms (including the carbon atoms of optional side chains), more preferably between 2 and 30, more preferably between 2 and 20, more preferably between 2 and 14, more preferably25 between 2 and 12, and still more preferably between 2 and 10 carbon atoms. The shortest atom chain between the oxygen atom (i.e. the oxygen of –O–L–NH2) and the NH2-group consists preferably of 2 to 14 atoms, more preferably of 2 to 12 atoms, more preferably of 2 to 10 atoms, more preferably of 2 to 8 atoms. In case the 30 shortest chain (which is the shortest possible connection between the oxygen at the anomeric center and the NH2-group) consists of 2 to 6 atoms, these are preferably

[0010] GAR-P04580WO13 Application (final).docx 10 carbon atoms. In case the shortest chain consists of 4 to 8 atoms, the chain may contain 1, 2 or 3 heteroatoms selected from O, N and S. In case the shortest chain consists of 9 to 14 atoms, the chain may contain 1, 2, 3, 4, 5, or 6 heteroatoms selected from O, N and S. 5 It is also preferred that the linker –L–, or the shortest chain is fully or partially fluorinated. The linker –L– may contain a 3-membered or a 4-membered or a 5-membered or a 6-membered saturated carbocycle or a 5-membered partly unsaturated (and not aromatic) carbocycle or a 4-membered or a 5-membered or a 10 6-membered saturated oxygen heterocycle or a 4-membered or a 5-membered or a 6-membered saturated nitrogen heterocycle or a 6-membered aromatic carbocycle. The linker –L– may also contain amide (–NH–CO–, –CO–NH–) and / or urea(–NH–CO–NH–) residues and preferably only one amide or urea residue. The linker 15 may also contain substituents and preferably two substituents, such as R10and R11, or four substituents such as R10, R11, R15and R14, which have the meanings as defined herein and which are preferably selected from: –F, –Cl, –CH3, –C2H5, –C3H7, –C5H9, –C6H13, –OCH3, –OC2H5, –CH2F, –CHF2, –CF3, –C(O)–NH2, –SCH3, –SC2H5, –NHC(O)CH3, –N(CH3)2, and –N(C2H5)2; 20 In case the linker –L– is fluorinated, more than two substituents –F are preferred. Preferably the linker –L– is selected from: –CH2–, –(CH2)2–, –(CH2)3–, –(CH2)4–,25 30 GAR-P04580WO13 Application (final).docx 11 5 GAR-P04580WO13 Application (final).docx 12 –Le– is selected from: –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–, –CH2–(O–CH2–CH2)p1–, –(CH2)p1–O–(CH2)p2–, –(CR14R15)p1–, , 5 10 –NHC(O)CH3, –N(CH3)2 and –N(C2H5)2; o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.15 Preferably, the linker –L– is selected from: –La–, –La–Le–, –La–Lb–Le– and–La–Ld–Le–; –La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, –(CH2–CH2–O)o–CH2–; –Lb– represents –O–; –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; –Ld– represents –(CH2)q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or20 –(CH2–CH2–O)q–CH2–; –Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–, –CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2–; o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6. 25 Preferably, the linker –L– represents –(CH2)o– and o is an integer selected from 1, 2, 3, 4, 5, 6, 7 and 8. GAR-P04580WO13 Application (final).docx 13 The saccharides of the present invention bear basic and / or acidic substituents and they may form salts with organic or inorganic acids or bases. Examples of suitable acids for such acid addition salt formation are hydrochloric acid, 5 hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic 10 acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, d-o- tolyltartaric acid, tartronic acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, and 15 other mineral or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. Examples of suitable inorganic or organic bases are, for example, NaOH, KOH, 20 NH4OH, tetraalkylammonium hydroxide, lysine or arginine and the like. Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of a base, selected out of the group mentioned above. 25 It is clear for the skilled person in the art of carbohydrate chemistry that the saccharides of general (I) are not containing –O–O– bonds and or sugar fragments(Ux, Ux+1, Ux+2, Ux+3) connected or bound to each other via their anomeric or C-1carbons. It is also clear for the person skilled in the art that the stereochemistry of the glycosidic bond is the stereochemistry indicated for the anomeric center of the30 sugar fragment in the general formula. Hence, the stereochemistry of the anomeric center for sugar fragment U1 and U5 is α, for sugar fragment U2 and U6 is β, for sugarfragment U3 is α and for sugar fragment U4 is α.The saccharide of general formula (I) contains a protective immunogenic epitope and35 is able to induce a protective immune response against P. gingivalis bacteria in ahuman and / or animal host. The saccharide of general formula (I) elicits antibodies that are cross-reacting with the P. gingivalis lipopolysaccharide, recognizespecifically P. gingivalis bacteria. Additionally, the inventive saccharides have theGAR-P04580WO13 Application (final).docx 14 advantage that these are pure synthesized compounds, which can be easily manufactured in accordance with GMP regulations. Thus, the vaccine composition of the present invention contains most preferably only 5one single compound of the general formula (I) bound to an immunogenic carrier,preferably a carrier protein and more preferably CRM197. Thus, the compound of the general formula (I) is useful for the preparation of well defined, well characterized andpure vaccines containing only one synthetically prepared and well characterized tri-, tetra-, penta-, hexa-, hepta- or octasaccharide preferably linked to an immunogenic10 carrier, preferably a carrier protein and more preferably CRM197. Consequently, the vaccines of the present invention contain only one synthetically synthesized compound of general formulae (I) preferably linked to an immunogenic carrier, preferably a carrierprotein and more preferably CRM197.15 Preferred is a saccharide of general formula (I), wherein x represents 1 and apharmaceutically acceptable salt thereof. Hence, a saccharide of general formula (I-a) 20 with L, T, and R1having the meaning defined herein, or a pharmaceutically acceptable salt thereof is particularly preferred. Also preferred is a saccharide of general formula (I), wherein x represents 3, and a25 pharmaceutically acceptable salt thereof. Thus, a saccharide of general formula (I-b), (I-b) GAR-P04580WO13 Application (final).docx 15 with L, T, and R1 having the meaning defined herein, or a pharmaceutically acceptablesalt thereof is also preferred.5 Also preferred is a saccharide of general formula (I), wherein x represents 1 or 3, R1represents -H, and a pharmaceutically acceptable salt thereof. Thus, a saccharide of general formulae (I-c) and (I-d), 10 with L and T having the meaning defined herein, or a pharmaceutically acceptable salt thereof are also preferred. Also preferred is a saccharide of general formula (I), wherein x represents 1 or 3, R1represents -H, T represents a bond or –Ux+3–, and a pharmaceutically acceptable salt15 thereof. Thus, a saccharide of general formula (II-a), (II-b), (II-c), or (II-d), GAR-P04580WO13 Application (final).docx 16 Preferably, T represents a bond, –Ux+3–, –Ux+3–Ux+2–, or –Ux+3–Ux+2–Ux+1–. Thus, asaccharide of general formula (I), (I-a) or (I-b), wherein T represents a bond, –Ux+3–, –Ux+3–Ux+2–, or –Ux+3–Ux+2–Ux+1– is preferred.5 Preferably, T represents a bond or –Ux+3–, wherein –Ux+3– is either –U4– or –U6–.Thus, a saccharide of general formula (I), (I-a) or (I-b), wherein T represents a bond or –Ux+3– , wherein –Ux+3– is either –U4– or –U6– is preferred.10 Also, preferred is a saccharide of general formula (III), H–Ux+2–Ux+1–Ux–[Ux+3–Ux+2–Ux+1–Ux]n–O–L–NH2(III) 15 wherein Ux, Ux+1, Ux+2, Ux+3, x, L, and n have the meanings as defined herein. Particularly preferred is a saccharide of general formula (III), wherein n represents 1 and R1represents –H. GAR-P04580WO13 Application (final).docx 17 Preferably the linker –L– represents –La–, –La–Le–, –La–Lb–Le–, or –La–Ld–Le– ; –La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, or –(CH2–CH2–O)o–CH2; –Lb– represents –O–, –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; 5 –Ld– represents –(CH2)q–, –(CH(OH))q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,–CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;and o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3,10 4, 5, and 6. Therefore, a saccharide of general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b),(II-c), (II-d), or (III) wherein15 –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,20 –CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;and o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6 is especially preferred.Particularly preferred is a saccharide of general formula (I), (I-a), (I-b), (I-c), (I-d),25 (II-a), (II-b), (II-c), (II-d), or (III), wherein 30 –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,–CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;and o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6; and R1represents –H. 35 It is particularly preferred that –L– represents –(CH2)o– and o is an integer selected from 2, 3, 4, 5, 6, 7 and 8. Thus, a particularly preferred saccharide is a saccharideof general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) wherein–L– represents –(CH2)o– and o is an integer selected from 2, 3, 4, 5, 6, 7 and 8. GAR-P04580WO13 Application (final).docx 18 Even more preferred is a saccharide of general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) wherein –L– represents –(CH2)o– and o is an integer selected from 2, 3, 4, 5, 6, 7 and 8 and R1represents –H. 5 Preferably, the inventive saccharide is selected from: 5-amino pentyl α-D- galactopyranosyl-(1→6)-α-D-glucopyranosyl--(1→4)-α-L-rhamnopyranosyl-(1→3)-β- D-N-acetylgalactopyranoside; 6-amino hexyl α-D-galactopyranosyl-(1→6)-α-D- glucopyranosyl--(1→4)-α-L-rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranoside;10 7-amino heptyl α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl--(1→4)-α-L- rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranoside; 4-amino butyl α-D- galactopyranosyl-(1→6)-α-D-glucopyranosyl--(1→4)-α-L-rhamnopyranosyl-(1→3)-β- D-N-acetylgalactopyranoside; 3-amino propyl α-D-galactopyranosyl-(1→6)-α-D- glucopyranosyl--(1→4)-α-L-rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranoside;15 5-amino pentyl α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl--(1→4)-α-L- rhamnopyranoside; 6-amino hexyl α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-- (1→4)-α-L-rhamnopyranoside; 7-amino heptyl α-D-galactopyranosyl-(1→6)-α-D- glucopyranosyl--(1→4)-α-L-rhamnopyranoside; 4-amino butyl α-D-galactopyranosyl- (1→6)-α-D-glucopyranosyl--(1→4)-α-L-rhamnopyranoside; 3-amino propyl α-D-20 galactopyranosyl-(1→6)-α-D-glucopyranosyl--(1→4)-α-L-rhamnopyranoside; 5-aminopentyl α-L-rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranosyl--(1→3)-α-D- galactopyranosyl-(1→6)-α-D-glucopyranoside; 6-amino hexyl α-L-rhamnopyranosyl- (1→3)-β-D-N-acetylgalactopyranosyl--(1→3)-α-D-galactopyranosyl-(1→6)-α-D- glucopyranoside; 7-amino heptyl α-L-rhamnopyranosyl-(1→3)-β-D-N-25 acetylgalactopyranosyl--(1→3)-α-D-galactopyranosyl-(1→6)-α-D-glucopyranoside; 4- amino butyl α-L-rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranosyl--(1→3)-α-D- galactopyranosyl-(1→6)-α-D-glucopyranoside; 3-amino propyl α-L-rhamnopyranosyl- (1→3)-β-D-N-acetylgalactopyranosyl--(1→3)-α-D-galactopyranosyl-(1→6)-α-D- glucopyranoside; 5-amino pentyl α-L-rhamnopyranosyl-(1→3)-β-D-N-30 acetylgalactopyranosyl--(1→3)-α-D-galactopyranoside; 6-amino hexyl α-L- rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranosyl--(1→3)-α-D- galactopyranoside; 7-amino heptyl α-L-rhamnopyranosyl-(1→3)-β-D-N- acetylgalactopyranosyl--(1→3)-α-D-galactopyranoside; 4-amino butyl α-L- rhamnopyranosyl-(1→3)-β-D-N-acetylgalactopyranosyl--(1→3)-α-D-35 galactopyranoside; and 3-amino propyl α-L-rhamnopyranosyl-(1→3)-β-D-N- acetylgalactopyranosyl--(1→3)-α-D-galactopyranoside. GAR-P04580WO13 Application (final).docx 19 Preferably, the inventive saccharide is selected from: 5-aminopentyl-α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside; 5-aminopentyl-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- 5galactopyranosyl- (1→3)-α-D-galactopyranoside; and5-aminopentyl-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranosyl-(1→6)-α-D-glucopyranoside.10 Conjugate Another aspect of the present invention is directed to a conjugate comprising a synthetic saccharide of general formula (I) covalently bound or covalently linked to an immunogenic carrier through the nitrogen atom of the –O–L–NH2group. In other words, another aspect of the present invention is directed to a saccharide of any of the15 general formulae (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) conjugatedwith an immunogenic carrier through the nitrogen atom of the –O–L–NH2group. The inventive conjugate comprising a synthetic saccharide of the general formula (I), (I-a),(I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) covalently bound or covalently linked toan immunogenic carrier through the nitrogen atom of the –O–L–NH2group is also 20 defined as a conjugate obtained by reacting a saccharide of any of the general formulae (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) with an immunogeniccarrier. Said conjugate proved to be efficient as a vaccine for immunization against diseases associated with Porphyromonas gingivalis bacteria.25 Saccharides are known by the person skilled in the art as generally TI-2 (T cell independent-2) antigens and poor immunogens. TI-2 antigens are antigens, which are recognized only by mature B cells through the cross linking of surface exposed immunoglobulin receptors. Without T cell help, no immunological memory is generated and neither isotype switching from IgM to other IgG subclasses, nor B 30 cells affinity maturation occurs. Moreover, saccharides are known as poor immunogens in humans due to the structural homology to human glycolipids and glycoproteins. Due to their poor immunogenic properties, saccharides manifest poor ability to produce both antibody production by B cells, as well as the formation of memory cells, features which are essential for the production of potent vaccines. 35 Therefore, to produce a potent saccharide-based vaccine, a saccharide of general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) is conjugated to animmunogenic carrier to provide a conjugate presenting increased immunogenicity in comparison with the saccharide. GAR-P04580WO13 Application (final).docx 20 Said conjugate consists of at least one synthetic saccharide of the general (I), (I-a),(I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) and an immunogenic carrier to whichthe at least one saccharide of the general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-5 b), (II-c), (II-d), or (III) is covalently bound.Surprisingly, it was found that immunization with a conjugate according to the present invention results in the production of high titers of antibodies specific to the carbohydrate part of the saccharide according to the present invention. Said10 antibodies are cross-reacting with the natural Porphyromonas gingivalis lipopolysaccharide, thus conferring protection against Porphyromonas gingivalis bacteria. In this context the term “immunogenic carrier” is defined as a structure, which is 15 conjugated to the saccharide to form a conjugate that presents an increased immunogenicity in comparison with the saccharide per se. Thus, the conjugation of a saccharides of the general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d),or (III) to the immunogenic carrier has as effect the stimulation of the immuneresponse against the saccharide of the general formula (I), (I-a), (I-b), (I-c), (I-d),20 (II-a), (II-b), (II-c), (II-d), or (III) without inducing an immune response against thesaid immunogenic carrier. Preferred immunogenic carriers are carrier proteins, P. gingivalis outer membraneproteins, or glycosphingolipids with immunomodulatory properties. For the person 25 skilled in the art, a carrier protein is a protein selected from the group comprising or consisting of: a diphtheria toxoid, a mutated diphtheria toxoid, a modified diphtheria toxoid, a mutated and modified diphtheria toxoid, a tetanus toxoid, a modified tetanus toxoid, a mutated tetanus toxoid, outer membrane protein (OMP), bovine serum albumin (BSA), keyhole limpet hemocyanine (KLH), cholera toxoid (CT) and protein30 D (a non-typeable Haemophilus influenzae protein).“P. gingivalis membrane proteins” are understood herein as proteins that are part ofor are present in the outer membrane of P. gingivalis (Mol Oral Microbiol. 2021,36(1):25-36) which can be recognized as virulence factors. Examples are but not35 restricted to fimbriae including long fimbriae, short fimbriae, cell surface proteins (e.g.40-kDa, 53-kDa and 67-kDa), hemagglutinin, porins such as RagA, RagB, PG1626,PG1414, PG1028, PG0694, and PG0695, and protease enzymes (gingipains) such as arginine-specific gingipains (RgpA, RgpB) and lysine-specific gingipain (Kgp). GAR-P04580WO13 Application (final).docx 21 The term “toxoid” as used herein refers to a bacterial toxin (usually an exotoxin), whose toxicity has been inactivated or suppressed either by chemical (formalin) or heat treatment, while other properties, typically immunogenicity, are maintained. A mutated toxoid as used herein is a recombinant bacterial toxin, which has been 5 amended to be less toxic or even non-toxic by amending the wild-type amino acid sequence. Such a mutation could be a substitution of one or more amino acids. Such a mutated toxoid presents on its surface a functionality that can react with the functional group Y of the interconnecting molecule to provide a modified toxoid. Said functionality is known to the person skilled in the art and includes but is not10 restricted to the primary amino functionality of a lysine residue that can react with activated esters, an isocyanate group or an aldehyde in presence of a reducing agent, to the carboxylate functionality of a glutamate or aspartate residue that can be activated by carbodiimides or to the thiol functionality of a cysteine residue. 15 Activated esters include, but are not restricted to N-(γ-maleimidobutyryloxy) sulfosuccinimide ester (sulfo-GMBS), succinimidyl (4-iodoacetyl) aminobenzoate (sulfo-SIAB), succinimidyl-3-(bromoacetamido)propionate (SBAP), disuccinimidyl glutarate (DSG), disuccinimidyl adipate (DSA), 2-pyridyldithiol-tetraoxatetradecane- N-hydroxysuccinimide (PEG-4-SPDP), bis-(4-nitrophenyl) adipate and bis-(4-20 nitrophenyl) succinate (see Figure 2). Preferred activated esters are disuccinimidyladipate (DSA), disuccinimidyl glutarate (DSG), bis-(4-nitrophenyl) adipate and bis-(4- nitrophenyl) succinate. Preferred is a conjugate of general formula (IV) 25 [H–Ux+2–Ux+1–Ux–T–O–L–NH–W]m–IM (IV)wherein m is comprised between about 2 and about 18; arepresents an integer from 1 to 10; b represents an integer from 1 to 4;IM represents an immunogenic carrier, and30 Ux, Ux+1, Ux+2, Ux+3, x, n and L have the meanings defined herein.GAR-P04580WO13 Application (final).docx 22 Preferably, m is comprised between 2 and 18. As well known to the skilled person, “m” in structure IV corresponds to the averageload of saccharide units per unit of immunogenic carrier as determined by MALDI-5 TOF MS method using the molecular weight of the immunogenic carrier as reference.By varying the reaction conditions for the coupling of the saccharide according to the present invention to the immunogenic carrier any conjugate of structure IV with mbeing comprised between about 2 and about 18, preferably between 2 and 18 can beobtained. 10 Preferably, the linker –L– is selected from: –La–, –La–Le–, –La–Lb–Le–, and –La–Ld–Le–; –La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, or –(CH2–CH2–O)o–CH2 ; –Lb– represents –O–, –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; 15 –Ld– represents –(CH2)q–, –(CH(OH))q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,–CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;and o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3,20 4, 5, and 6. It is also preferred that –W– representsand a is an integer selected from 2, 3, 4, 5 and 6 is especially preferred. Hence, a conjugate of general formula (IV), wherein the linker –L– is selected from: –La–, –La–Le–, –La–Lb–Le–, and –La–Ld–Le–;25 –La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, or –(CH2–CH2–O)o–CH2; –Lb– represents –O–, –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; –Ld– represents –(CH2)q–, –(CH(OH))q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,30 –CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6; –W– representsand a is an integer selected from 2, 3, 4, 5 and 6 is especially preferred. , Preferred is also conjugate of general formula (IVa) GAR-P04580WO13 Application (final).docx 23 [H–Ux+2–Ux+1–Ux–T–O–L–NH–W]m–CP (IVa)wherein m is comprised between about 2 and about 18; –W– is selected from: 5a represents an integer from 1 to 10;b represents an integer from 1 to 4;CP represents a carrier protein, andUx, Ux+1, Ux+2, Ux+3, x, n and L have the meanings defined herein.10 Preferably, m is comprised between 2 and 18. As well known to the skilled person, “m” in structure IVa corresponds to the averageload of saccharide units per unit of carrier protein as determined by MALDI-TOF MS method using the molecular weight of carrier protein as reference. By varying the 15 reaction conditions for the coupling of the saccharide according to the present invention to the carrier protein any conjugate of structure IVa with m being comprisedbetween about 2 and about 18, preferably between 2 and 18 can be obtained.Preferably, the linker –L– is selected from: –La–, –La–Le–, –La–Lb–Le–, and 20 –La–Ld–Le–; –La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, or –(CH2–CH2–O)o–CH2 ; –Lb– represents –O–, –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; –Ld– represents –(CH2)q–, –(CH(OH))q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or –(CH2–CH2–O)q–CH2– ;25 –Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,–CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;and o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6. 30 GAR-P04580WO13 Application (final).docx 24 It is also preferred that –W– representsand a is an integer selected from 2, 3, 4, 5 and 6 is especially preferred. Hence, a conjugate of general formula (IV), wherein the linker –L– is selected from: –La–, –La–Le–, –La–Lb–Le–, and –La–Ld–Le–; 5 –La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, or –(CH2–CH2–O)o–CH2 ; –Lb– represents –O–, –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; –Ld– represents –(CH2)q–, –(CH(OH))q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,10 –CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6; and a is an integer selected from 2, 3, 4, 5 –W– representsand 6 is especially preferred. , The cysteine residue on the carrier protein can be converted to the corresponding 15 dehydroalanine that can be further reacted with a suitable interconnecting molecule to provide modified carrier protein having on their surface the functional group X of the interconnecting molecule. It is especially preferred that the inventive saccharides described herein are20 conjugated to the non-toxic mutated diphtheria toxin CRM197 presenting as afunctionality a primary amine functionality of a lysine residue. CRM197 like wild-type diphtheria toxin is a single polypeptide chain of 535 amino acids (58 kD) consisting of two subunits linked by disulfide bridges having a single 25 amino acid substitution of glutamic acid for glycine. It is utilized as a carrier protein in a number of approved conjugate vaccines for diseases such as Prevnar®. Thus, in a preferred embodiment of the present invention the carrier protein presents on its surface primary amino functionalities of lysine residues that are able to react 30 with the functional group Y of the interconnecting molecule to provide modified carrier protein having on their surface said functional group X of the interconnecting molecule, which is able to react with the terminal amino group of the linker functionalizing the inventive saccharides. GAR-P04580WO13 Application (final).docx 25 Said functional group X of the interconnecting molecules is selected from the group comprising or consisting of maleimide; ^-iodoacetyl; ^-bromoacetyl; and N- hydroxysuccinimide ester (NHS), aldehyde, imidoester, carboxylic acid, alkyl 5 sulfonate, sulfonyl chloride, epoxide, anhydride, carbonate (see Figure 3). Even more preferred is a conjugate of general formula (V), [H–Ux+2–Ux+1–Ux–T–O–L–NH–W]m–CRM197(V)10 wherein m is comprised between about 2 and about 18; –W– is selected from: arepresents an integer from 1 to 10;b represents an integer from 1 to 4, andUx, Ux+1, Ux+2, Ux+3, x, n and L have the meanings defined herein.15 Preferably, m is comprised between 2 and 18. Also preferred is a conjugate of general formula (V), wherein x represents 1 or 3. Thus, a conjugate of general formula (V-a), or (V-b), 20 GAR-P04580WO13 Application (final).docx 26 wherein m is comprised between about 2 and about 18; –W– is selected from: a represents an integer from 1 to 10; 5 b represents an integer from 1 to 4; T, L, and R1 have the meaning defined herein.Preferably, m is comprised between 2 and 18. 10 Also preferred is a conjugate of general formula (V), wherein T represents a bond or –Ux+3–, wherein –Ux+3– is either –U4– or –U6–. Thus, a conjugate of general formula(VI-a), (VI-b), (VI-c), or (VI-d), GAR-P04580WO13 Application (final).docx

[0011] wherein m is comprised between about 2 and about 18; –W– is selected from: a represents an integer from 1 to 10; 5 b represents an integer from 1 to 4; T, L, and R1have the meaning defined herein, is also preferred. Preferably, m is comprised between 2 and 18. GAR-P04580WO13 Application (final).docx 28 In another embodiment, the immunogenic carrier is a P. gingivalis outer membraneprotein. The conjugation of P. gingivalis outer membrane protein with a saccharideof the present invention may enhance the immunogenicity of the saccharide as both immunogenic components address the same pathogen. 5 Thus, preferred is also conjugate of general formula (IV), wherein IM represents a P. gingivalis outer membrane protein, and m, –W–, Ux, Ux+1, Ux+2, Ux+3, x, n and Lhave the meanings defined herein.10 Particularly preferred is, when the P. gingivalis outer membrane protein is selectedfrom long fimbriae, RagA, RagB, RgpA, RgpB, and Kgp. Also preferred is a conjugate of general formula (VII-a) or (VII-b), wherein PGOMPrepresents a P. gingivalis outer membrane protein as defined herein15 wherein m is comprised between about 2 and about 18; –W– is selected from:GAR-P04580WO13 Application (final).docx 29 a represents an integer from 1 to 10; b represents an integer from 1 to 4; T, L, and R1have the meaning defined herein. 5 Preferably, m is comprised between 2 and 18. Also preferred is a conjugate of general of general formula (VIII-a), (VIII-b), (VIII-c), or (VIII-d), wherein PGOMP represents a P. gingivalis outer membrane protein asdefined herein 10 GAR-P04580WO13 Application (final).docx

[0012] wherein m is comprised between about 2 and about 18; –W– is selected from: a represents an integer from 1 to 10; 5 b represents an integer from 1 to 4; T, L, and R1have the meaning defined herein, is also preferred. Preferably, m is comprised between 2 and 18.10 Preferably, in general formulae (IV), (IVa), (V), (V-a), (V-b) (VI-a), (VI-b), (VI-c),(VI-d), (VII-a), (VII-b) (VIII-a), (VIII-b), (VIII-c), and (VI-d) the linker –L– is selected 15 –(CH2–CH2–O)q–CH2– ;GAR-P04580WO13 Application (final).docx 31 –Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,–CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ;o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3, 4, 5, and 6; –W– representsand a is an integer selected from 2, 3, 4, 5 and 6. 5 Especially preferred is a conjugate of general formula (IV), (IVa), (V), (V-a), (V-b), (VI-a), (VI-b), (VI-c), (VI-d), (VII-a), (VII-b) (VIII-a), (VIII-b), (VIII-c), or (VI-d), wherein the linker –L– represents –(CH2)o– ,o is an integer selected from 2, 3, 4, 5, 6, 7 and 8; –W– representsnd a is an integer selected from 2, 3, 4, 5 and 10 It is also preferred that R1– represents –H in general formulae (IV), (V), (IVa), (V-a),(V-b) (VI-a), (VI-b), (VI-c), (VI-d), (VII-a), (VII-b) (VIII-a), (VIII-b), (VIII-c), and (VI-d). Thus, particularly preferred is a conjugate of general formula (IV), (V), (V-a), (V-b) (VI-a), (VI-b), (VI-c), (VI-d), (VII-a), (VII-b) (VIII-a), (VIII-b), (VIII-c), or (VI-d), wherein15 R1– represents –H, the linker –L– represents –(CH2)o–,o is an integer selected from 2, 3, 4, 5, 6, 7 and 8; –W– representsnd a is an integer selected from 2, 3, 4, 5 and Preferably m is comprised between about 2 and about 18, more preferably between about 5 and about 15, even more preferably between about 8 and about 12. 20 Preferably m is comprised between 2 and 18, more preferably between 5 and 15, even more preferably between 8 and 12. In another embodiment, said immunogenic carrier is preferably a glycosphingolipid25 with immunomodulatory properties, and more preferably (2S,3S,4R)-1-(^-D- galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol. The term glyco- sphingolipid with immunomodulatory properties, as used herein, refers to a suitable glycosphingolipid capable of stimulating the immune system's response to a target antigen, but which does not in itself confer immunity as defined above. 30 GAR-P04580WO13 Application (final).docx 32 Glycosphingolipids as used herein are compounds containing a carbohydrate moiety α–linked to a sphingolipid. Preferably, the carbohydrate moiety is a hexopyranose and most preferably is α-D-galactopyranose. For the person skilled in the art, sphingolipids are a class of lipids containing a C18 amino alcohol connected via an5 amide bond to a fatty acid. The C18 amino alcohol is preferably mono-, di- orpolysubstituted with hydroxyl groups. Especially preferred, the C18 amino alcohol is phytosphingosine. The fatty acid is preferably a monocarboxylic acid having a saturated alkyl chain of a number of carbons ranging from 16 to 28 and more preferably from 18 to 26. Glycosphingolipids with immunomodulatory properties10 include, but they are not restricted to (2S,3S,4R)-1-(^-D-galactopyranosyl)-2- hexacosanoylaminooctadecane-3,4-diol, which can stimulate natural killer (NK) activity and cytokine production by natural killer T (NKT) cells and exhibits potent antitumor activity in vivo (Proc. Natl Acad. Sci. USA, 1998, 95, 5690).15 The conjugates of the inventive saccharides with a glycosphingolipid with immunomodulatory properties have the advantage of being heat stable. To be suitable for conjugation, on the glycosphingolipid with immunomodulatory properties a functionality is introduced. Said functionality is prone to react directly with the terminal amino group of the linker of the inventive to provide conjugates of the 20 saccharides or with the functional group Y of the interconnecting molecule to provide the modified glycosphingolipid with immunomodulatory properties. Preferably, said functionality is introduced at the C6 of the carbohydrate moiety of the glycosphingolipid with immunomodulatory properties. Thus, the glycosphingolipid 25 with immunomodulatory properties is functionalized with a functionality, which is prone of reacting with the terminal amino group of the saccharides or with thefunctional group Y of the interconnecting molecule. A functionality prone to react with an amino group includes, but it is not restricted to activated ester, isocyanate group, aldehyde, epoxide, imidoester, carboxylic acid, alkyl sulfonate and sulfonyl 30 chloride. A functionality prone to react with the functional group Y of the interconnecting molecule so that to provide the modified glycosphingolipid with immunomodulatory properties presenting the functional group X of the interconnecting molecule includes, but it is not restricted to amine, alcohol, thiol, activated ester, isocyanate group, aldehyde, epoxide, vinyl, imidoester, carboxylic35 acid, alkyl sulfonate, sulfonyl chloride, vinyl group, alkynyl group and azido group. Preferably, the functionality introduced at the C-6 position of the carbohydrate moiety of the glycosphingolipid with immunomodulatory properties is selected from the group comprising or containing an amine, a thiol, an alcohol, a carboxylic acid, a vinyl, GAR-P04580WO13 Application (final).docx 33 maleimide, ^-iodoacetyl, ^-bromoacetyl, N-hydroxysuccinimide ester (NHS), 2- pyridyldithiols. Said functional group X of the interconnecting molecules is selected from the group 5 comprising or consisting of maleimide, ^-iodoacetyl, ^-bromoacetyl, N- hydroxysuccinimide ester (NHS), aldehyde, carboxylic acid, epoxyde, alkyl sulfonate, sulfonyl chloride, anhydride, carbonate. Preferably, di(N-succinimidyl) adipate or bis(4-nitrophenyl) adipate is first reacted10 with a synthetic saccharide having a primary amino group. Activated saccharide is subsequently condensed with a glycosphingolipid, which is modified at C-6 position by an interconnecting molecule having a terminal amino functionality in order toafford the conjugate. 15 As used herein, the term “interconnecting molecule” refers to a bifunctional molecule containing functional group X and functional group Y, wherein functional group X is capable of reacting with the terminal amino group on the linker –L– and the functionalgroup Y is capable of reacting with a functionality present on the immunogenic carrier. 20 As used herein, the term “interconnecting molecule” refers to a bifunctional molecule containing functional group X and functional group Y, wherein functional group X is capable of reacting with the terminal amino group on the linker –L– and the functionalgroup Y is capable of reacting with a functionality present on the immunogenic 25 carrier. Thus, in another preferred embodiment the conjugate has the structure of general formula (IX) H–Ux+2–Ux+1–Ux–T–O–L–NH–W‘–GSL (IX)30 –W’– represents –L2^NH^L3– ;L3represents ^L3´^L3´´^L3´´´^ or ^L3´^L3´´´^ or ^L3´^; and L3´, L3´´, and L3´´´are independently of each other selected from: ^CH2^,^C2H4^, 35 ^C3H6^, ^C4H8^,^C5H10^, ^C6H12^, ^C7H14^, ^C8H16^, ^C9H18^,^C10H20^, ^CR23R24^, ^CR25R26^, ^CR27R28^, ^CR29R30^, ^CR31R32^,^CR33R34^, –(CH2–CH2^O)o^; –o–C6H4–, –m–C6H4–, –p–C6H4–, ^CH2^S^CH2^,^CH2^O^CH2^, ^S^, ^O^; GAR-P04580WO13 Application (final).docx 34 GAR-P04580WO13 Application (final).docx 35 E is selected from m, n, p represent independently of each other an integer from 0 to 30; GSL represents a glycosphingolipid,R23 – R34 are independently of each other selected from: –H, –F, –Cl, –CH3,5 –C2H5, –C3H7, –C5H9, –C6H13, –OCH3, –OC2H5, –CH2F, –CHF2, –CF3, –C(O)–NH2, –SCH3, –SC2H5, –NHC(O)CH3, –N(CH3)2, and –N(C2H5)2; and Ux, Ux+1, Ux+2, Ux+3, x, and L have the meanings defined herein. In a preferred embodiment of the conjugate of general formula (IX), L2is selected10 from: and m and n represent independently of each other an integer from 0 to 30. GAR-P04580WO13 Application (final).docx 36 In a further preferred embodiment the glycosphingolipid GSL has the followingstructure: 5 wherein R2is selected from , R3is ^(X1)p1^(X2)p2^(X3)p3^X4; R4and R5are selected from ^H and ^OH and cannot be simultaneously the same; R6is ^(Y1)m1^(Y2)m2^(Y3)m3^Y4; 10 GAR-P04580WO13 Application (final).docx 37 GAR-P04580WO13 Application (final).docx 38 p1, p2, p3, m1, m2 and m3 represent independently of each other an integer from 0to 30; In a particularly preferred embodiment, the glycosphingolipid is (2S,3S,4R)-1-(^-D- 5 galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol (α-galactosylceramide). 10 Also preferred is a conjugate of general of general formula (X-a), (X-b), (X-c), or (X-d), wherein GSL represents a glycosphingolipid as defined herein GAR-P04580WO13 Application (final).docx 39 wherein R1, W’, L and GSL have the meanings as defined herein.It was found that the saccharide of general formula (I), (I-a), (I-b), (I-c), (I-d), (II-a),(II-b), (II-c), (II-d), or (III) covalently linked or covalently bound to an immunogenic 5 carrier through the nitrogen atom of the –O–L–NH2group or in other words the conjugate obtained by reacting a saccharide of general formula formula (I), (I-a), (I- b), (I-c), (I-d), (II-a), (II-b), (II-c), (II-d), or (III) with an immunogenic carrier, andespecially a conjugate of general formula (IV), (IVa), (V), (V-a), (V-b), (VI-a), (VI-b),(VI-c), (VI-d), (VII-a), (VII-b) (VIII-a), (VIII-b), (VIII-c), (VIII-d), (IX), (X-a), (X-b), (X-c),10 or (X-d), elicits a protective immune response in a human and / or animal host, and therefore is useful in the prevention and / or treatment of a disease caused by P. gingivalis . Such disease includes periodontal disease, Alzheimer's disease,atherosclerosis, or rheumatoid arthritis. 15 Pharmaceutical compositionA further aspect of the present invention relates to a pharmaceutical composition or avaccine containing at least one synthetic saccharide and / or a pharmaceutically acceptable salt thereof according to the present invention and / or a conjugate 20 comprising a saccharide according to the present invention covalently linked to an immunogenic carrier, preferably to CRM197 carrier protein, through the nitrogen atomof the -O-L-NH2 group together with at least one pharmaceutically acceptableadjuvant and / or excipient.GAR-P04580WO13 Application (final).docx 40 The term “adjuvant” as used herein refers to an immunological adjuvant i.e. a material used in a pharmaceutical composition or vaccine that modifies or augmentsthe effects of said pharmaceutical composition or said vaccine by enhancing theimmune response to a given antigen contained in the pharmaceutical composition or5 vaccine without being antigenically related to it. For the persons skilled in the art, classically recognized examples of immunological adjuvants include, but are not restricted to oil emulsions (e.g. Freund's adjuvant), saponins, aluminium or calcium salts (e.g. alum), non-ionic block polymer surfactants, and many others.10 Pharmaceutical compositions or vaccines are preferably in aqueous form, particularlyat the point of administration, but they can also be presented in non-aqueous liquid forms or in dried forms e.g. as gelatin capsules, or as lyophilisates, etc.. Pharmaceutical compositions or vaccines may include one or more preservatives,such as thiomersal or 2-phenoxyethanol. Mercury-free compositions are preferred,15 and preservative-free vaccines can be prepared. Pharmaceutical compositions or vaccines may include a physiological salt, such as asodium salt e.g. to control tonicity. Sodium chloride (NaCl) is typical and may be present at between 1 and 20 mg / ml. Other salts that may be present include 20 potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc. Pharmaceutical compositions or vaccines can have an osmolality of between200 mOsm / kg and 400 mOsm / kg.Pharmaceutical compositions or vaccines may include compounds (with or without25 an insoluble metal salt) in plain water (e.g. w.f.i.), but will usually include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminium hydroxide adjuvant); or a citrate buffer. Buffer salts will typically be included in the 5-20 mM range. 30 Pharmaceutical compositions or vaccines typically have a pH between 5.0 and 9.5,e.g. between 6.0 and 8.0. Pharmaceutical compositions or vaccines are preferably sterile and gluten free.35 Pharmaceutical compositions or vaccines are suitable for administration to animal(and, in particular, human) patients, and thus include both human and veterinary uses. They may be used in a method of raising an immune response in a patient, comprising the step of administering the composition to the patient. GAR-P04580WO13 Application (final).docx 41 The pharmaceutical compositions or vaccines of the present invention may beadministered before a subject is exposed to Porphyromonas gingivalis and / or after a subject is exposed to Porphyromonas gingivalis. Pharmaceutical compositions or vaccines may be prepared in unit dose form. In 5 some embodiments a unit dose may have a volume of between 0.1-1.0 mL e.g. about 0.5 mL. Pharmaceutical compositions or vaccines of the invention may be prepared in various forms. For example, the pharmaceutical compositions or vaccines may be10 prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared (e.g. a lyophilized composition or a spray-freeze dried composition). Thecomposition may be prepared for topical administration e.g. as an ointment, cream or powder. The composition may be prepared for oral administration e.g. as a tablet or 15 capsule, as a spray, or as a syrup (optionally flavored). The composition may be prepared for pulmonary administration e.g. by an inhaler, using a fine powder or a spray. The composition may be prepared as a suppository. The composition may be prepared for nasal, aural or ocular administration e.g. as a spray or drops. Injectables for intramuscular administration are typical. 20 A therapeutically effective dosage of one conjugate according to the present invention or of one saccharide of general formula (I) refers to that amount of the compound that results in an at least a partial immunization against a disease. Toxicity and therapeutic efficacy of such compounds can be determined by standard 25 pharmaceutical, pharmacological, and toxicological procedures in cell cultures or experimental animals. The dose ratio between toxic and therapeutic effect is the therapeutic index. The actual amount of the composition administered will be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgement of the prescribing 30 physician. Antibody A further embodiment of the present invention relates to a monoclonal antibody 35 having specificity for the saccharide of general formula (I) or a fragment thereof. Said antibody is able to prevent and treat diseases caused by Porphyromonas gingivalis. Thus, the monoclonal antibody is useful for passive immunization against Porphyromonas gingivalis infections by providing a fast immune response in anysubject. The monoclonal antibody is particularly useful for passive immunization GAR-P04580WO13 Application (final).docx 42 against Porphyromonas gingivalis infections in a subject having a deficient immuneresponse and who does not respond to active immunization. The term fragment of a saccharide of general formula (I) refers to constituting 5 subunits of a saccharide of general formula (I). For example, if the saccharide of general formula (I) is a hexasaccharide, then a fragment thereof includes penta-, tetra-, tri-, di- and monosaccharides, which are the constituting units of thehexasaccharide. 10 The term “antibody” as used herein encompasses polyclonal and monoclonal antibody preparations, as well as preparations including hybrid antibodies, F(ab’)2fragments, F(ab) molecules, single domain antibodies and functional fragments thereof, which exhibit immunological binding properties of the parent antibody molecule. The antibody disclosed herein may be a monoclonal antibody.15 In a preferred embodiment, the monoclonal antibody or a fragment thereof hasspecificity for the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl- (1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranosideand trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-20 galactopyranosyl- (1→3)-α-D-galactopyranoside.In a preferred embodiment, the monoclonal antibody or a fragment thereof hasspecificity for the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl- (1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside or25 the trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranoside.In a preferred embodiment, the monoclonal antibody or a fragment thereof bindsselectively to the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-30 (1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranosideand trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranosyl- (1→3)-α-D-galactopyranoside.In a preferred embodiment, the monoclonal antibody or a fragment thereof binds35 selectively to the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside orthe trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranoside.GAR-P04580WO13 Application (final).docx 43 Preferably, the monoclonal antibody has been raised against a conjugate according to the present invention. 5Thus, in a preferred embodiment, the monoclonal antibody or a fragment thereof hasbeen raised against a conjugate of the tetrasaccharide α-D-galactopyranosyl-(1→6)- α-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranoside and a carrier protein orthe monoclonal antibody or a fragment thereof has been raised against a conjugate10 of the trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranoside and a carrier protein.In a further preferred embodiment, the monoclonal antibody or a fragment thereofhas been raised against the glycoconjugate 1-CRM197 or 2-CRM197. 15 Preferably, the monoclonal antibodies of the present invention having specificity for the saccharide of general formula (I) or a fragment thereof were generated via conventional hybridoma technology following immunization of mice with a glycoconjugate according to the present invention. 20 Preferred monoclonal antibodies of the present invention are characterized by theirability to recognize the saccharide of formula (I) or a fragment thereof in a glycan- specific and dose-dependent manner, as evidenced by binding assays and competitive specificity profiles described herein. The monoclonal antibodies of the25 present invention particularly exhibited high specificity for tetrasaccharide 1, with negligible cross-reactivity to structurally related glycan analogues, thereby confirming their fine epitope discrimination. Functional reactivity was demonstrated through ELISA assays using lipopolysaccharide isolated from Porphyromonas gingivalis, a pathogen known to present the native form of tetrasaccharide 1. These values reflect30 strong apparent affinities to the native antigen. Thus, the present invention is also directed to a monoclonal antibody that specificallybinds to the saccharide of formula (I) or a fragment thereof, wherein the antibody is characterized by:35 a) specific binding to the saccharide of formula (I) or a fragment thereof asdetermined by glycan microarray analysis; and b) binding to the Porphyromonas gingivalis lipopolysaccharide as detected in anenzyme-linked immunosorbent assay (ELISA). GAR-P04580WO13 Application (final).docx 44 Thus, in a preferred embodiment, the monoclonal antibody or a fragment thereof- binds to the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside or the trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- 5galactopyranosyl- (1→3)-α-D-galactopyranoside; and- binds to the Porphyromonas gingivalis lipopolysaccharide; and- has been raised against a conjugate of the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→3)- 2-acetamido-2-deoxy-β-D-galactopyranoside and a carrier protein or against a10 conjugate of the trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy- β-D-galactopyranosyl- (1→3)-α-D-galactopyranoside and a carrier protein.In a preferred embodiment, the monoclonal antibody has an Ig1 isotype and κ-type light chains (see Figure 17). Thus, in a preferred embodiment, the monoclonal 15 antibody or a fragment thereof -binds to the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside or the trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranoside; and20 - binds to the Porphyromonas gingivalis lipopolysaccharide; and- has been raised against a conjugate of the tetrasaccharide α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→3)- 2-acetamido-2-deoxy-β-D-galactopyranoside and a carrier protein or against aconjugate of the trisaccharide α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-25 β-D-galactopyranosyl- (1→3)-α-D-galactopyranoside and a carrier protein; and- has an Ig1 isotype and κ-type light chains.In another embodiment, the monoclonal antibody according to the invention have specificity for (or binds to) the saccharide of formula (I) or a fragment thereof with an30 EC₅₀ value of less than 1 µg / mL in an ELISA assay (see Figure 16).In another embodiment, the monoclonal antibody according to the invention does not substantially bind to structurally related glycans as determined by glycan microarray screening. 35 In another embodiment, the monoclonal antibodies of the present invention are generated by hybridoma technology from mice immunized with glycoconjugate 1-CRM197 or 2-CRM197. GAR-P04580WO13 Application (final).docx 45 In another embodiment, the monoclonal antibody according to the invention is produced by a hybridoma selected from the group consisting of F5, G12, F12, and E12. 5 The hybridomas were deposited on April 11, 2025 under the provisions of theBudapest Treaty with the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Inhoffenstraße 7B, 38124 Braunschweig; Germany by the Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1,10 14476 Potsdam, Germany. Thus another aspect of the present invention is directed to a hybridoma selected from the group consisting of F5, G12, F12, and E12. Preferably, the hybridoma is F5, more preferably CD4E1F5. 15 Also disclosed herein is a vaccine composition comprising a monoclonal antibodyhaving specificity for the saccharide of general formula (I) or a fragment thereof, and a pharmaceutically acceptable carrier. 20 The vaccine composition typically includes one or more pharmaceutically acceptable carriers (e.g., sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like). Water is a more typical carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose 25 and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatine, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skimmilk, glycerol, propylene glycol, water, ethanol, and the like. The vaccine composition, if desired, can also 30 contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. For prophylactic treatment against Porphyromonas gingivalis infection, the35 monoclonal antibody or the vaccine composition can be administered prior to exposure of a subject to the bacteria so that the resulting immune response can inhibit or reduce the severity of the bacterial infection such that the bacteria can be eliminated from said subject. GAR-P04580WO13 Application (final).docx 46 Also, the monoclonal antibody or the vaccine composition can be administered postinfection or after presumed infection, exposure or manifestation of clinical symptoms. In an aspect thereof, the monoclonal antibody or the vaccine composition can be administered in a time period up to 8 hours post infection. Alternatively, the 5 monoclonal antibody combination is administered in a time period up to 24 hours post infection. In a further alternative, the monoclonal antibody combination is administered in a time period up to 48 hours post infection. The monoclonal antibody or the vaccine composition may be administered, including 10 as a single dose or in multiple sequential doses, up to 8 hours post infection (8hpi), 12hpi, 18hpi, 24hpi, 36hpi, 48hpi, 72hpi, 1 day post infection, 2 days post infection, 3 days post infection, 4 days post infection, 5 days post infection, 6 days post infection 7 days post infection, a week post infection, 10 days post infection, 2 weeks post infection, 3 weeks post infection, 4 weeks post infection, a month post infection,15 months post infection. Various delivery systems are known and can be used to administer the monoclonal antibody. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, 20 intrarectal, and oral routes. The therapeutic agent can be administered, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, and the like). Immunological assay 25 A further embodiment of the present invention is directed to a saccharide according to the present invention for use as marker in immunological assays for detection of antibodies against Porphyromonas gingivalis. Such assays comprise, for instance,microarray and ELISA. 30 Hence, the inventive saccharide can be used for diagnosis of diseases caused by Porphyromonas gingivalis. An assay conducted for diagnostic purposes according to the invention may be an immune assay like a solid-phase enzyme immunoassay(EIA), an enzyme linked immunosorbent assay (ELISA), especially an “indirect"ELISA or a radioimmune assay (RIA). Preferably, the saccharide according to the 35 present invention is covalently linked on the solid support through an interconnecting molecule. Thus, the saccharide according to the present invention can be covalentlylinked on the solid support directly or indirectly through the nitrogen atom of the -O-L-NH2group. The solid support is preferably selected from the group comprising GAR-P04580WO13 Application (final).docx 47 or consisting of: a glass slide, a microtitre plate, test tubes, microspheres, nanoparticle or beads. It is particularly preferred that the solid support is a glass slide or a microtitre plate. 5 A microtitre plate or microplate or microwell plate is a flat plate with multiple "wells" used as small test tubes. Typically, a microtitre plate having 6, 24, 96, 384 or even 1536 sample wells can be used. Microplates are produced from many different materials, like polycarbonate for microtitre plate used for PCR. The most common is polystyrene as used for most optical detection microplates. It can be colored white by 10 the addition of titanium dioxide for optical absorbance or luminescence detection or black by the addition of carbon for fluorescent biological assays. Afurther embodiment of the present invention is directed to an in-vitro method fordetecting the presence of Porphyromonas gingivalis bacteria in a sample comprising15 the steps: a) providing a sample; b) contacting the sample with the inventive monoclonal antibody; and c) detecting the presence of Porphyromonas gingivalis bacteria in the sample.20 Preferably the in-vitro method according to the present invention enables the detection of Porphyromonas gingivalis bacteria in a sample, and even morepreferably of Porphyromonas gingivalis W50 bacteria.Preferably the sample is selected from a blood sample, serum sample, pleural fluid 25 sample, sputum sample and urine sample. Preferably the in-vitro method according to the present invention can be conductedusing a commonly known assay format such as an enzyme-linked immunosorbent assay (ELISA), western blot, microarray, immunofluorescence imaging and lateral30 flow immunochromatographic assay. In molecular biology the use of commercially available kits is becoming ever the more popular. They include all components needed for performing a specific test and / or analysis arrangement in reasonable amounts. Often some or all of the components 35 are already dissolved in a suitable test solution or buffer in useful concentrations. Therefore, one aspect of the present invention relates to a kit for detecting thepresence of Porphyromonas gingivalis bacteria in a sample comprising(a) at least one antibody of the present invention or fragments thereof.40 GAR-P04580WO13 Application (final).docx 48 Preferred, the kit according to the invention comprises at least the following components: (a) at least one antibody of the present invention or fragments thereof(b) at least one further antibody5 (c) a standard solution.The following components may also be included in such kits: (d) a blocking solution(e) a wash solution and / or10 (f) a sample buffer.The at least one further antibody in the kit may be a specific antibody which can be used as a capture antibody. Preferably it is an enzyme-linked secondary antibody used as detection antibody that binds specifically to an antigen or to antibody's Fc 15 region. Alternatively, it may be a secondary antibody linked to a dye used as detection antibody that binds specifically to an antigen or to antibody's Fc region. For quantitative determinations, the optical density (OD) or fluorescence of the sample is compared to a standard curve, which is typically a serial dilution of a known- concentration solution of the target molecule, which is most preferably the saccharide20 of formula (I) or a very similar LPS (a standard solution). A blocking solution may bea solution of a non-reacting protein, such as bovine serum albumin or casein, which is added to block any plastic surface in the well that remains uncoated by the antigen. Washing solutions are used to remove unbound components. A sample buffer may be used to dilute the sample of the patient (blood, serum, urine) so that 25 the concentration of the target molecule is in the range which can normally be detected by the test system used.30Description of the figures Figure 1: shows a repeating unit of the O-antigen of Porphyromonas gingivalis LPS. 35 Figure 2: Commercially available interconnecting molecules . Figure 3: Examples of functional group X of the interconnecting molecule. Figure 4: Shows two CRM197 conjugates of the present invention.GAR-P04580WO13 Application (final).docx 49 Figure 5: Characterization of conjugates CRM197-tetrasaccharide 1 andCRM197-trisaccharide 2. (A) MALDI-TOF-MS spectra of glyco-conjugate 1. (B) MALDI-TOF-MS spectra of glycoconjugate 2.5 (C) 12% SDS-PAGE of 1 µg CRM197, glycoconjugate 1 and glyco-conjugate 2. The PageRuler Prestained Protein Ladder was used as amolecular weight marker. The average carbohydrate to protein loadingwas 4.5 for glycoconjugate 1 and 7.7 for glycoconjugate 2.10 Figure 6: Glycan microarray analysis of antibody binding in sera of micevaccinated with glycoconjugate 1, glycoconjugate 2 and PBS-CRM197.Mean Fluorescence Intensity of (A): IgG antibody (B): IgM and (C): IgA (D): exemplary glycan array screens, one serum per group, day 56, Values represent mean ± SEM. 15 Figure 7: Glycan microarray analysis of antibody binding in saliva of micevaccinated with glycoconjugate 1, glycoconjugate 2 and PBS-CRM197.Mean Fluorescence Intensity of (A): IgG antibody (B): IgM and (C): IgA (D): exemplary glycan array screens, pooled saliva, day 70, Values20 represent mean ± SEM. Figure 8: Glycan microarray analysis of hybridoma. Mean Fluorescence Intensityof IgG antibody binding to tetrasaccharide 1. Values represent mean ± SEM. Differences were tested for significance to secondary antibody25 only using one sample t test with (****) p<0.0001, (**) p<0.01. Figure 9: Bacterial ELISA with P. gingivalis W50, 1: sera of mice immunized with1-CRM197, 2: sera of mice immunized with 2-CRM197, CRM: mice immunized with CRM197, 1-hybridoma: antibodies generated against 1 30 with the hybridoma technology, Values represent mean ± SEM. Differences were tested for significance to secondary antibody only using one sample t test with N=3, *: p<0.0332. Figure 10: Determination of human IgG and IgA antibodies binding to synthesized35 LPS-fragments 1-11 and positive control 5.06. (A) Fluorescence signalsindicating IgG antibody binding in saliva of one exemplary chronic periodontitis patient, (B) fluorescence signals indicating IgA antibody binding in saliva of one exemplary healthy, and (C) associated printing pattern. (D-G) Mean fluorescence intensity (MFI) indicating IgG or IgA GAR-P04580WO13 Application (final).docx 50 titer of bound human IgG or IgA antibodies in saliva or serum to glycan library. Figure 11: Mean fluorescence intensity (MFI) indicating IgG titer of bound human5 IgG antibodies in saliva to glycan library with labeled outlayers.Figure 12: Determination of human antibodies in saliva binding to terminal α(1→3)-rhamnose glycans. P-T-01 and P-H-01 are masked. **P ≤ .01, ns – notsignificant, two-sided unpaired t test. 10 Figure 13: Determination of human antibodies in saliva binding to terminal α(1→3)-rhamnose glycans. P-T-01 and P-H-01 are masked. **P ≤ .01, ns – notsignificant, two-sided unpaired t test. 15 Figure 14: Mean Fluorescence Intensity of binding of monoclonal antibodies E12, F11, F12 and F5 (10000 ng / mL) to synthetic glycans 1 and 2 measuredby Glycan microarray. Figure 15: Binding of monoclonal antibodies E12, F11, F12 and F5 in different20 dilutions (0.005, 0.05, 0.5, 5, 50, 100 and 200 µg / mL) to commercial LPS (InvivoGen, Cat.# tlrl-pglps) measured by ELISA. Figure 16: Binding of monoclonal antibodies E12, F11, F12 and F5 in differentdilutions (0.005, 0.05, 0.5, 5, 50, 100 and 200 µg / mL) to P. gingivalis25 W50 measured by ELISA. Figure 17: Isotyping of monoclonal antibodies F5, F11, E12 and F12 using a mousemonoclonal antibody isotyping test kit (BIO-RAD, REF: MMT1). All antibodies are of IgG1 isotype having κ type light chains.30 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those skilled in the art that the techniques disclosed in the examples, which follow represent techniques discovered by the 35 inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those skilled in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments, which are disclosed and still obtain a like or similar result. GAR-P04580WO13 Application (final).docx 51 Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the 5 purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as 10 would be apparent to one skilled in the art after having the benefit of this description of the invention. Examples 15 A. Chemical synthesis General Information All chemicals were reagent grade and used as supplied unless otherwise noted. All 20 solvents for chemical reactions were commercially purchased in p.a. quality. If stated, they were dried in a Solvent Dispensing System (J.C. Meyer). For HPLC and MS spectrometry, solvents with corresponding quality were used. Water was used from a Milli Q-station from Millipore. The automated syntheses were performed on ahome-built synthesizer developed at the Max Planck Institute of Colloids and25 Interfaces. Reaction completion, identity, and purity of all compounds were determined by low resolution mass spectrometry (ESI-LRMS) or analytical thin-layer chromatography (TLC). TLC was performed on Merck silica gel 60 F254 plates (0.25 mm). Compounds were visualized by UV irradiation (254 nm) or stained (5% sulfuric acid 30 in ethanol or Hanessian's Stain: 235 mL of distilled water, 12 g of ammonium molybdate, 0.5 g of ceric ammonium molybdate, and 15 mL sulfuric acid). Flash column chromatography was performed on Kieselgel 60 with 230-400 mesh (Sigma-Aldrich, St. Louis, USA). Analysis and purification by normal and reverse phase HPLC and ESI-LRMS was performed by using an Agilent 1200 series.1H,13C, 35 COSY and HSQC NMR spectra were recorded in parts per million (^) relative to the resonance of the solvent on a Varian 400-MR (400 MHz), Varian 600-MR (600 MHz), or Bruker Biospin AVANCE700 (700 MHz) spectrometer. Assignments were supported by COSY and HSQC experiments. High resolution mass spectra (HRMS) GAR-P04580WO13 Application (final).docx 52 were obtained using 6210 ESI-TOF mass spectrometer (Agilent) and MALDI-TOF autoflex™ (Bruker) instruments.Abbreviations 5Ac AcetylAcOH Acetic acidAc2O Acetic anhydrideBAIB BisacetyliodobenzeneBn Benzyl10 tBuOH t-ButanolBz BenzoylCAN Cericammonium nitrateCbz BenzyloxycarbonylClAc Chloroacetate15 Cu(OAc)2Copper(II) acetate DBU 1,8-Diazabicyclo[5.4.0]undec-7-eneDCC N,N’-DicyclohexylcarbodiimideDCM DichloromethaneDMAP N,N-Dimethylaminopyridine20 DMF N,N’-DimethylformamideESI ElectrosprayionizationEt3N TriethylamineEt EthylEtOAc Ethyl acetate25 FmocCl 9-Fluorenylmethylchloroformateg Gramsh HoursHRMS High resolution mass spectrometryLev Levulinyl30 min MinutemL MillilitreMe MethylMeI Methyl iodideMeOH Methanol35 MP p-Methoxy phenylMS Molecular sievesNaHCO3Sodium bicarbonate NaOH Sodium hydroxideNaOMe Sodium methoxideGAR-P04580WO13 Application (final).docx 53 NAP 2-naphthalenylmethylNIS N-Iodo succinimideNMR Nuclear magnetic resonancePd / C Palladium on charcoal5 Ph PhenylPico PicoloylCPS Capsular polysaccharidePy PyridineRT Room temperature10 TCA TrichloroacetylTEMPO 2,2,6,6-TetramethylpiperidinyloxyTfOH Trifluromethanesulfonic acidTMSOTf TrimethylsilyltrifluromethanesulfonateTHF Tetrahydrofuran15 Tol p-TolylMaterials and Measurements Solvents used for dissolving all building blocks and making of various solutions were taken from Solvent Dispensing System (J.C. Meyer). Wash solvents were HPLC20 grade. Prior to automated synthesis, the building blocks were weighed and co- evaporated three times with anhydrous toluene and dried for at least one hour under high vacuum prior to use. All solutions were freshly prepared in oven-dried, argon- flushed glassware and kept under argon during the automation process. Isolated product yields were calculated on the basis of resin loading. Functionalized resin R225 was synthesized as previously reported (Green Chem. 2006, 8, 861-867) and resinloading (0.40 mmol / g) was determined following a published protocol (Chem. Rev.1996, 96, 683-720). Resin was placed in the reaction vessel and was swollen indichloromethane for 20 min at room temperature before starting the first module. During this time, all reagent lines involved in the synthesis were washed and primed. 30 Galactosamine building block 5.02 was purchased from GlycoUniverse GmbH & CO KGaA. 35 Preparation of Stock Solutions GAR-P04580WO13 Application (final).docx 54 Building Block Solution: Thioglycoside building block was dissolved in 1 mL (per cycle) of anhydrous CH2Cl2. Activator Solution / Acidic Wash Solution: TMSOTf (0.9 mL, 0.62 mmol) was added to 80 mL of anhydrous CH2Cl2.5 Pre-Capping Solution: Pyridine (10 mL) was added to 90 mL of DMF. Capping Solution: Methanesulfonic acid (1.2 mL, 18.5 mmol) and acetic anhydride(6 mL, 63.5 mmol) were added to 50 mL of anhydrous CH2Cl2.Lev Deprotection Solution: N2H4∙ HOAc (725 mg, 7.87 mmol) was dissolved in 50 mL of a 4:1:0.25 mixture of pyridine / acetic acid / water. 10 Fmoc Deprotection Solution 1: Piperidine (20 mL) was added to 80 mL anhydrous DMF. Fmoc Deprotection Solution 2: Et3N (20 mL) was added to 80 mL anhydrous DMF. ClAc Deprotection Solution: Thiourea (2.5 g, 32.84 mmol) was dissolved in 55 mL of a 10:1 mixture of 2-methoxyethanol / pyridine. 15 Modules for Automated Synthesis Initiation: The resin loaded in the reaction vessel is washed with DMF, THF, and CH2Cl2(3 x 3 mL for 15 s, respectively). The resin is then swollen in 2 mL CH2Cl2for 20 20 minutes while the temperature of the reaction vessel is cooled to the lowest temperature required throughout the synthesis. Module I - Acidic Washing: Once the temperature of the reaction vessel hasadjusted to the desired temperature of the subsequent glycosylation by the cooling 25 device, 1 mL of the Acidic Wash Solution is delivered to the reaction vessel through the precooling device (set at -20 °C). After three minutes, the solution is drained. Finally, the resin is washed with 3 mL CH2Cl2(bubbling = 15 s) and drained. Module IIa – Glycosylation (for thioglycosides): Upon draining the CH2Cl2 in the30 reaction vessel, 1 mL of Building Block Solution 1 containing the appropriate building block is delivered from the building block storing component to the reaction vessel. After the temperature reaches the desired temperature (T1), Activator Solution 1 (1 mL) is delivered to the reaction vessel from the respective activatorstoring component to the reaction vessel The glycosylation mixture is incubated for 35 the selected duration (t1) at the desired T1, the reaction temperature is linearly ramped to T2 (rate = 4 °C / min). Once T2 is reached, it is maintained, and the reactionmixture is incubated for an additional time (t2). Once the incubation time is finished, the reaction mixture is drained and the resin is washed with CH2Cl2(1 x 2 mL for 15 s), then dioxane (1 x 2 mL for 15 s), and finally CH2Cl2(2 x 2 mL for 15 s). GAR-P04580WO13 Application (final).docx 55 Module IIIa - Capping: The resin is washed with DMF (2 x 3 mL for 15 s). Then Pre-capping Solution (2 mL) is delivered, and the reaction temperature is adjusted toand maintained at 50 °C 5 for one minute (max power = 5 W). The resin is then washed with CH2Cl2(3 x 2 mL for 15). Upon washing, Capping Solution (4 mL) is delivered and the temperature is adjusted and maintained 25 °C). The resin and the reagents are incubated for 8 min. The solution is then drained from the reactor vessel and the resin is washed with CH2Cl2(3 x 3 mL for 15 s). 10 Module IVa - Fmoc Deprotection 1: The resin is first washed with DMF (3 x 3 mLfor 15 s), and then Fmoc Deprotection Solution 1 (2 mL) is delivered to the reaction vessel. The temperature of the reagents inside the reactor vessel is then adjusted to and maintained at 60 °C. After 1 min the reaction solution is drained and the resin is 15 washed with DMF (3 x 3 mL for 15 s) and CH2Cl2(5 x 3 mL for 15 s). After this module the resin is ready for the next glycosylation cycle. Module IVb - Lev Deprotection: The resin is washed with CH2Cl2 (3 x 2 mL for15 s), and then Lev Deprotection Solution (2 mL) is delivered to the reaction20 vessel. The temperature of the reagents inside the reactor vessel is then adjusted to and maintained at 25 °C. After 5 min, the reaction solution is drained from the reactor vessel and the resin is washed with CH2Cl2(3 x 2 mL for 15 s). Then, of fresh Lev Deprotection Solution (2 mL) is delivered and the process is repeated twice more. Then, the resin is washed with DMF, THF, and CH2Cl2(3 x 3 mL for 15 s,25 respectively). After this module the resin is ready for the next glycosylation cycle. Module IVc - Fmoc Deprotection 2: The resin is first washed with DMF (3 x 3 mLfor 15 s), and then Fmoc Deprotection Solution 2 (2 mL) is delivered to the reaction vessel. The temperature of the reagents inside the reactor vessel is then adjusted to and maintained at 60 °C. After 5 min the reaction solution is drained and the resin is 30 washed with DMF (3 x 2 mL for 15 s). Then, fresh Fmoc Deprotection Solution 2 (2 mL) is delivered and the process is repeated twice more. Then, the resin is washed with DMF (3 x 3 mL) and CH2Cl2(3 x 3 mL) for 15 s each time. After this module the resin is ready for the next glycosylati 35 Module IVe – ClAc Deprotection: The resin is first washed with CH2Cl2 (3 x 2 mLfor 15 s) then ClAc Deprotection Solution (2 mL) was delivered to the reaction vessel. The temperature of the reagents inside the reactor vessel is then adjusted to and maintained at 90 °C. After 22 min, the reaction solution is drained from the reactor vessel. The resin is washed with DMF (3 x 2 mL for 15 s). Then fresh ClAc GAR-P04580WO13 Application (final).docx 56 Deprotection Solution 2 (2 mL) is delivered, and the process is repeated twicemore. Then, the resin is washed with DMF (3 x 3 mL for 15 s) and CH2Cl2(5 x 3 mL for 15 s). After this module the resin is ready for the next glycosylation cycle. 5 Post-automated Synthesis Manipulations, Analysis and Purification Cleavage from Solid Support (Method A-1): Protected Oligosaccharides After automated synthesis, the resin was removed from the reaction vessel, suspended in CH2Cl2(20 mL), and photocleaved in a continuous-flow photoreactor. A Vapourtec E-Series easy-MedCHem, equipped with a UV-150 Photochemical reactor10 having a UV-150 Medium- Pressure Mercury Lamp (arc length 27.9 cm, 450 W)surrounded by a long-pass UV filter (Pyrex, 50% transmittance at 305 nm) was used. A Pump 11 Elite Series (Harvard Apparatus syringe pump at a flow rate of 0.8 mL / min was used to pump the mixture through a FEP tubing (i.d. 3.0 inch, volume: 12 mL) at 20 °C. The reactor was washed with 20 mL CH2Cl2at a flow rate of 2.0 15 mL / min. The output solution was filtered to remove the resin and the solvent was evaporated in vacuo. Crude was then analyzed by MALDI. Deprotection of Oligosaccharides AGA-synthesized and photocleaved product was subjected to methanolysis and 20 hydrogenolysis. The hydrogenolysis product was purified by RP-HPLC and lyophilized on a Christ Alpha 2-4 LD plus freeze dryer to afford the final deprotected compound. Methanolysis (Method C): To a solution of protected oligosaccharide in 25 MeOH:CH2Cl2(2 mL, 1:1), sodium methoxide (0.5 M solution in MeOH, 2.2 equiv. per ester group) was added. The mixture was stirred at room temperature for 2 h. Then Amberlite IR-120 (H+form) was added to quench. After neutralization, the reaction mixture was filtered, and the solvent was removed in vacuo. The crude compoundwas used for hydrogenolysis without further purification. 30 Hydrogenolysis (Method D): The crude compound obtained after methanolysis was dissolved in 4 mL of EtOAc:t-BuOH:H2O (2:1:1). Pd / C (10%) was added to the solution and the suspension was stirred in a H2 bomb with 60 psi pressure over night. The insoluble material was removed by a CHROMAFIL ®Xtra, RC 0.45 syringe 35 filter. The solid was washed once with t-BuOH and several times with water. The filtrate was collected and concentrated in vacuo. Analytical NP-HPLC of Crude Material (Method B-2) GAR-P04580WO13 Application (final).docx 57 Analytical NP-HPLC was conducted on an Agilent 1200 Series system. A YMC-Diol- 300-NP column (150 mm x 4.60 mm I.D.) was used at a flow rate of 1.00 mL / min with hexane / EtOAc as eluent (20% EtOAc in hexane for 5 min, 20 → 55% EtOAc in hexane over 35 min, 55 → 100% EtOAc in hexane over 35 min, 100% EtOAc for 10 5 min). Analytical / preparative RP-HPLC of Crude Material (Method E-1) Crude products were dissolved in water and analyzed / purified using analytical / preparative HPLC. A Thermo-Scientific Hypercarb column (150 mm x10 4.60 mm I.D.) was used for analytical RP-HPLC with a flow rate of 0.70 mL / min withwater (0.1% HCO2H) / acetonitrile as eluents (100% H2O (0.1% HCO2H) for 5 min, 0 → 30% acetonitrile in H2O (0.1% HCO2H) over 30 min, 30 → 100% acetonitrile in H2O (0.1% HCO2H) over 5 min, 100% acetonitrile for 5 min). 15 GAR-P04580WO13 Application (final).docx 58 Example A.1: Preparation of Rhamnose Building Blocks 5.04a and 5.04b5 Scheme 1. Synthetic route to rhamnose building blocks 5.04a and 5.04b.4-Methylphenyl 2,3-O-(1-methylethylidene)-4-O-(2-naphthalenylmethyl)-1-thio-α-L-rhamnopyranoside (5.12)10 Rhamnopyranose 5.11 (Trends Microb. 2003, 11, 554-561) (4.13 g, 15.3 mmol, 1.0equiv.) was dissolved in anhydr. acetone (60 mL). 2,2,-Dimethoxypropane (7.5 mL,61.2 mmol, 4.0 equiv.) was added followed by para-toluenesulfonic acid (582 mg, 3.1mmol, 0.2 equiv.). The reaction mixture was stirred for 6 hat room temperature.Then, it was quenched by the addition of sat. aq. NaHCO3, filtered and concentrated15under reduced pressure. The residue was extracted with CH2Cl2(2 x 100 mL), dried over Na2SO4, filtered and concentrated. 2,3-Isopropylidene product (3.7 g, 11.9 mmol,78%) was obtained as a colorless solid after purification by column chromatography (Hex:AcOEt 3:1). Rf = 0.48 (Hex:AcOEt, 3:1). The residue (3.7 g,11.9 mmol, 1.0 equiv.) was dissolved in dry N,N-dimethylformamide (40 mL). The20 stirred solution was cooled to 0 °C and sodium hydride (1.1 g, 27.4 mmol; 60%dispersion in mineral oil, 2.3 eq.) was added in small portions. After 30 min, NAPBr(4.0 g, 17.9 mmol, 1.5 equiv.) was added. The reaction mixture was allowed to warmGAR-P04580WO13 Application (final).docx 59 up to room temperature and was stirred over night. Methanol (10 mL) was added, thereaction mixture was stirred for 10 min and afterwards diluted with ethyl acetate (100mL). The organic layer was washed with water (2 x 100 mL). The aqueous phasewas extracted with ethyl acetate (2 x 100 mL). The combined organic phase was5 washed with water (100 mL), dried over Na2SO4 and concentrated. Product 5.12 (4.0g, 8.9 mmol, 75%) wasobtained as a colorless oil after purification by column chromatography (Hex:AcOEt 9:1 to 3:1). Rf = 0.8 (Hex:AcOEt, 1:1).1H NMR (400 MHz, CDCl3) δ 7.88 – 7.83 (m, 4H), 7.56 – 7.46 (m, 3H), 7.42 – 7.3710 (m, 2H), 7.17 – 7.12 (m, 2H), 5.71 (s, 1H), 4.98 (dd, J = 108.5, 11.8 Hz, 2H), 4.41 –4.39 (m, 1H), 4.23 (dd, J = 9.8, 6.2 Hz, 1H), 3.42 – 3.35 (m, 1H), 1.55 (s, 3H), 1.43(s, 3H), 1.30 (d, J = 6.2 Hz, 3H) ppm.13C NMR (101 MHz, CDCl3) δ 137.9, 135.8, 133.3, 133.1, 132.6, 129.9, 129.8,128.2, 128.0, 127.8, 126.9, 126.2, 126.0, 109.5, 84.3, 81.5, 78.6, 76.8, 73.2, 66.2,15 28.2, 26.6, 21.2, 17.9 ppm.HRMS (QToF): Calcd for C27H30O4SNa [M + Na]+ 473.1757; found 473.1743.4-Methylphenyl 4-O-(2-naphthalenylmethyl)-1-thio-α-L-rhamnopyranoside (5.13) 20 2,3-Isopropylidene 5.12 (4.0 g, 8.8 mmol, 1.0 equiv.) was dissolved in acetic acid / water (9:1, 50 mL) solution and reacted for 18 h at 50 °C. The mixture wasconcentrated and purified by column chromatography (Hex:AcOEt 3:1 to 1:1) to25 obtain title compound 5.13 (3.6 g, 1.7 mmol, 99%) as a colorless syrup. Rf = 0.27 (Hex:AcOEt, 1:1).1H NMR (400 MHz, CDCl3) δ 7.90 – 7.76 (m, 4H), 7.53 – 7.46 (m, 3H), 7.40 – 7.31(m, 2H), 7.12 (dd, J = 8.2, 4.1 Hz, 2H), 5.41 (d, J = 1.7 Hz, 1H), 4.92 (d, J = 3.2 Hz,2H), 4.32 – 4.23 (m, 1H), 4.19 (dd, J = 3.4, 1.6 Hz, 1H), 3.97 (dd, J = 9.1, 3.4 Hz, 1H),30 3.47 (t, J = 9.2 Hz, 1H), 2.33 (s, 3H), 1.39 (d, J = 6.2 Hz, 3H) ppm.13C NMR (101 MHz, CDCl3) δ 137.9, 135.7, 133.4, 133.2, 132.3, 130.3, 130.0,129.9, 128.7,128.1, 127.9, 126.9, 126.4, 126.3, 125.9, 87.9, 82.0, 75.3, 72.7, 72.0,68.7, 21.3, 18.1 ppm. HRMS (QToF): Calcd for C24H26O4SNa [M + Na]+ 433.1444; found 433.1432.35 GAR-P04580WO13 Application (final).docx 60 4-Methylphenyl 3-O-benzyl-4-O-(2-naphthalenylmethyl)-1-thio-α-L-oside (5.14) 5Diol 5.13 (7.0 g, 17.1 mmol, 1.0 equiv.) was dissolved in MeOH (100 mL) and Bu2SnO(8.5 g, 34.2 mmol, 2.0 equiv.) w reaction mixture ed up to65 °C and stirred at the same vernight. The re was co-evaporated with toluene and d h vacuum. The c olved inDMF (100 mL) and benzyl brom e ( . 5 m , 20.5 mmol, 1.2 e quiv.), and CsF (3.4 g,10 22.2 m aunder pthen di adried 8obtaine das a colorless oil after purification by column chromatog 15 9:1 to 3:1). Rf = 0.41 (Hex:AcOEt, 3:1).1H NMR (400 MHz, CDCl3) δ 7.86 – 7.76 (m, 4H), 7.53 – 7.43 (m, 3H), 7.41 – 7.32(m, 7H), 7.12 (d, J = 8.2 Hz, 2H), 5.47 (d, J = 1.8 Hz, 1H), 4.94 (dd, J = 91.4, 11.2 Hz,2H), 4.74 (s, 2 3.59 (t, J = 9.320 Hz, 1H), 2.33 ( 13C NMR (10 132.2, 130.3,130.0, 128.8, 1 28.3, 128.2, 128.1, 128.1, 127.8, 126.8, 126.2, 126.1, 126.0, 87.5,80.3, 80.2, 75.6, 72.3, 70.2, 68.8, 21.3, 18.0 ppm.HRMS (QToF): Calcd for C31H32O4SNa [M + Na]+ 523.1913; found 523.1924.25 GAR-P04580WO13 Application (final).docx 61 4-Methylphenyl 3-O-benzyl-2-O-levulinyl-4-O-fluorenylmethoxycarbonyl-1-thio-α-L-rhamnopyranoside (5.15a) 5 To a solution of 5.14 (800 mg, 1.6 mmol, 1.0 equiv.) and LevOH (0.33 mL, 3.2 mmol, 2.0equiv.) in anhydrous CH2Cl2(15 mL) was added DIC (0.75 mL, 4.8 mmol, 3.0 equiv.) and 4- DMAP (39 mg, 0.32 mmol, 0.2 equiv.) at 0 °C. The reaction wasstirred at room temperature overnight. The reaction mixture was filtered through10 Celite, the filtrate was washed withaqueous NaHCO3and the aqueous phase wasextracted with CH2Cl2. The combined organic phase was dried over Na2SO4, filtered and concentrated. Sugar 5.15a (810 mg, 1.35 mmol,85%) was obtained as acolorless syrup after purification by column chromatography (Hex:AcOEt 3:1). Rf =0.35 (Hex: EtOAc 3:1). To a well stirred emulsion of sugar 5.15a (810 mg, 1.3 mmol,15 1.0 equiv.) in CH2Cl2 / water (7:1, 24 mL), was added DDQ (337 mg, 1.5 mmol, 1.1equiv.) and the suspension was stirred at room temperature for 1.5 h protected from light.The mixture was diluted with CH2Cl2, washed with 10% Na2S2O3and saturated aqueous NaHCO3solution. The organic layer was dried over Na2SO4, filtered, concentrated and th phy (Hex:AcOEt 9:120 to 3:1) to obtain 3-O rless solid. Rf = 0.35(Hex:AcOEt 3:1). T ol, 1.0 equiv.) andanhydrous pyridine ( . , . , . . CH2Cl2 (15 mL) at 0°C was added FmocCl (524 mg, 2.0 mmol, 1.5 equiv.) followed by 4-DMAP (8 mg, 0.1mmol, 0.05 equiv.) was added and the reaction mixture was stirred for two hours at 0 25 °C. Aqueous citric acid solution (10 mL) was added and the mixturewas allowed towarm up to room temperature. The aqueous phase was extracted with CH2Cl2and the combined organic phase was dried over Na2SO4, filtered and concentrated. The title compound 5.04a (840 mg, 1.2 mmol, 91%) was obtained as a white solid afterpurification by column chromatography (Hex:AcOEt = 19:1 to 3:1).30 Rf = 0.25 (Hex:AcOEt 3:1).[α]D -39.32 cm-1 (c 1, CHCl3).IR (film): 3067, 2872, 1749, 1723, 1603, 1495, 1451, 1386, 1246, 1152, 1102, 986,848, 784, 738, 698 cm-1.HRMS (QToF): Calcd for C40H40O8SNa [M + Na]+ 703.2336; found 703.2354.35 1H NMR (400 MHz, CDCl3): δ 7.79 (d, J = 7.5 Hz, 2H), 7.67 – 7.57 (m, 2H), 7.46 –7.36 (m, 2H), 7.35 – 7.30 (m, 4H), 7.26 – 7.20 (m, 5H), 7.12 (d, J = 7.9 Hz, 2H), 5.57GAR-P04580WO13 Application (final).docx 62 (dd, J = 3.3, 1.7 Hz, 1H), 5.35 (d, J = 1.6 Hz, 1H), 4.88 (t, J = 9.8 Hz, 1H), 4.65 (d, J= 11.9 Hz, 1H), 4.52 – 4.40 (m, 3H), 4.35 (dd, J = 9.8, 6.2 Hz, 1H), 4.26 (t, J = 7.2Hz, 1H), 3.88 (dd, J = 9.7, 3.2 Hz, 1H), 2.68 (ddd, J = 10.8, 5.1, 1.3 Hz, 4H), 2.33 (s,3H), 2.15 (s, 3H)5 13C NMR (101 143.31, 141.45,138.30,137.41, 127.34, 125.23, 120.25, 86.32, 74.97, 71.56, 70.41, 70.13, 67.50, 46.94, 38.10, 29.93, 28.24, 21.29, 17.43 ppm. 10 4-Methylphenyl 2-O-benzoyl 3-O-benzyl-4-O-fluorenylmethoxycarbonyl-1-thio- α-L-rhamnopyranoside (5.04b) 15 To a solution of 5.14 (5.0 g, 10.0 mmol, 1.0 equiv.) in anhydrous pyridine (10 mL), BzCl (3.48 mL, 30.0 mmol, 3.0 equiv.) was added at 0 °C under an argonatmosphere. The mixture was allowed to warm up to room temperature and stirredfor 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic phase was washedwith aqueous citric acid solution (10% v / v)20 and brine, dried over Na2SO4, filtered and concentrated. The benzoylated 5.15b (5.6g, 9.3 mmol, 93%) was obtained as a colorless syrup after purification by columnchromatography (Hex / EA 9:1). Rf = 0.41 (Hex: EtOAc 9:1). To a well stirred emulsionof 5.15b (5.5 g, 9.1 mmol, 1.0 equiv.) in CH2Cl2 / water (7:1, 48 mL), was added DDQ(1.3 g, 10.0 mmol, 1.1 equiv.) and the suspension was stirred at room temperature for25 1.5 h protected from light. The mixture was diluted with CH2Cl2, washed with 10%aqueous Na2S2O3 and saturated aqueous NaHCO3 solution. The organic layer was dried over Na2SO4, filtered, concentrated and the residue was purified by columnchromatography (Hex / EA 9:1 to 3:1) to obtain the 4-OH-sugar (3.8 g, 6.5 mmol,71%) as a colorless solid. Rf = 0.41 (Hex:EA3:1). To a solution of 4-OH-sugar (3.830 g, 8.2 mmol, 1.0 equiv.) and anhydrous pyridine (3.31mL, 40.9 mmol, 5.0 equiv.) inanhydrous CH2Cl2 (60 mL) at 0 °C was added FmocCl (3.2 g, 1.5 mmol, 1.5 equiv.)followed by 4-DMAP (50 mg, 0.4 mmol, 0.05 equiv.) was added and the reactionmixture was stirred for two hours at 0 °C. Aqueous citric acid solution (30 mL) was added and the mixture was allowed to warm up to room temperature. The aqueous35 phase was extracted with CH2Cl2 and the combined organic phase was dried overNa2SO4, filtered and concentrated. The title compound 5.04b (4.9 g, 7.1 mmol, 87%)GAR-P04580WO13 Application (final).docx 63 was obtained as a white solid after purification by column chromatography (Hex / EtOAc = 19:1 to 3:1). Rf = 0.69 (Hex:EA 3:1).5 , HRMS (QToF): Calcd for C42H38O7SNa [M+ Na]+ 709.2230; found 709.2250.1H NMR (600 MHz, CDCl3): δ 8.10 – 8.05 (m, 2H), 7.79 (d, J = 7.5 Hz, 2H), 7.66 –7.53 (m, 3H), 7.49 – 7.39 (m, 4H), 7.38 – 7.25 (m, 6H), 7.22 (q, J = 2.5 Hz, 3H),10 7.13 (d, J = 8.2 Hz, 2H), 5.80 (dd, J = 3.3, 1.7 Hz, 1H), 5.50 (d, J = 1.8 Hz, 1H), 5.06(t, J = 9.8 Hz, 1H), 4.65 (dd, J = 94.5, 12.1 Hz, 2H), 4.47 (d, J = 7.3 Hz, 2H), 4.42(dd, J = 9.8, 6.2 Hz, 1H), 4.26 (t, J = 7.2 Hz, 1H), 4.01 (dd, J = 9.7, 3.3 Hz, 1H), 2.33(s, 3H), 1.32 (d, J = 6.3 Hz, 3H) ppm.13C NMR (151 MHz, CDCl3): δ 165.8, 155.0, 143.5, 143.3, 141.5, 141.4, 138.3, 137.4,15133.5,132.5, 130.1, 130.1, 129.7, 129.6, 128.6, 128.5, 128.1, 127.9, 127.3, 125.2, 125.2, 120.2, 86.6, 77.4, 75.0, 71.6, 70.9, 70.1, 67.7, 47.0, 21.3, 17.6 ppm. Example A.2: Preparation of Galactose Building Block 5.0320 Scheme 2. Synthetic route to α-galactose building block 5.03. GAR-P04580WO13 Application (final).docx 64 Ethyl 2-O-benzyl-3-O-(2-naphthalenylmethyl)-4,6-O-[(S)-phenylmethylene]-1- thio-β-D- galactopyranoside (5.08)5 OH-galactose (7.4 g, 16.4 mmol, 1.0 equiv.) was dissolved in anhydrous DMF (75mL). The stirred solution was cooled to 0 °C and sodium hydride (1.5 g, 24.6 mmol;6 ,.10 afterwards diluted with ethyl acetate (100 mL). The organic layer was washed withwater (2 x 100 mL). The aqueous phase was extracted with ethyl acetate (2 x 100mL). The combined organic phase was washed with water (100 mL), dried over Na2SO4 and concentrated. Product 5.08 (8.8 g, 16.2 mmol, 99%) was obtained as a15 colorless solid after purification by column chromatography (SiO2, Hex / EtOAc = 3:1).Rf = 0.22 (Hex / EtOAc 3:1).1H NMR (700 MHz, CDCl3) δ 7.87 – 7.78 (m, 3H), 7.74 – 7.69 (m, 1H), 7.57 – 7.29 (m,13H), 5.48 (s, 1H), 4.96 – 4.87 (m, 4H), 4.44 (d, J = 9.7 Hz, 1H), 4.30 (dd, J = 12.3, 1.8Hz, 1H), 4.17 (d, J = 3.7 Hz, 1H), 3.96 – 3.90 (m, 2H), 3.65 (dd, J = 9.2, 3.5 Hz, 1H),20 3.35 – 3.32 (m, 1H), 2.90 – 2.73 (m, 2H), 1.34 (t, J = 7.5 Hz, 3H) ppm.13C NMR (176 MHz, CDCl3) δ 138.6, 138.1, 135.9, 133.4, 133.2, 129.2, 128.5,128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 126.7, 126.7, 126.3, 126.1, 126.0, 101.7,84.6, 81.1, 77.1, 75.9, 74.2, 72.1, 69.9, 69.5, 24.0, 15.2 ppm.HRMS (QToF): Calcd for C33H34O5SNa [M + Na]+ 565.2019; found 565.2018.25 GAR-P04580WO13 Application (final).docx 65 Ethyl 4-O-benzoyl-2,6-bis-O-benzyl-3-O-(2-naphthalenylmethyl)-1-thio-β-D-galactopyranoside (5.09) 5Compound 5.08 (2.0 g, 3.7 mmol, 1.0 equiv.) was co-evaporated with anhydroustoluene (2 x3 mL), and dissolved in anhydrous CH2Cl2(20 mL). Triethylsilane (3.5 mL, 22.1 mmol, 6.0equiv.) and trifluoroacetic anhydride (0.52 mL, 3.7 mmol, 1.0 equiv.) were added and the solution was cooled to 0 °C. Trifluoroacetic acid (1.7 mL, 22.1 mmol, 6.0 equiv.) was added dropwise. The mixture was allowed to warm up to10 room temperature and was stirred for 5 h. The solution was diluted with CH2Cl2 andquenched with saturated aqueous NaHCO3 (40 mL). The aqueous phase wasextracted with CH2Cl2 (2 x 60 mL) and the combined organic phase was washed withwater (60 mL), dried over Na2SO4, filtered and concentrated.4-OH-galactose (1.8 g,3.3 mmol, 90%) was obtained as a colorless syrup after purification by column15 cgsar 20 water and the aqueous layer was extract d with th l acetate The combined organicphase was washed with 1.0 M HCl a Na2SO4, filtered andconcentrated. The title compound 5.09 %) was obtained as a colorless oil after purification by column EtOAc = 9:1 to 3:1). Rf = 0.31 (Hex:EA 3:1). 25 HRMS (QToF): Calcd for C40H40O6SNa [M + Na]+ 671.2438; found 671.2488.1H NMR (400 MHz, CDCl3): δ 8.16 – 7.98 (m, 3H), 7.81 – 7.68 (m, 3H), 7.65 – 7.56(m, 2H), 7.52 – 7.13 (m, 14H), 5.94 (dd, J = 3.3, 1.0 Hz, 1H), 5.02 (d, J = 11.6 Hz,1H), 4.89 – 4.66 (m, 3H), 4.57 – 4.36 (m, 3H), 3.84 (d, J = 1.2 Hz, 1H), 3.77 (d, J =30 3.3 Hz, 1H), 3.75 – 3.61 (m, 2H), 3.58 (d, J = 7.1 Hz, 1H), 2.78 – 2.66 (m, 2H), 1.34(t, J = 7.5 Hz, 3H) ppm.13C NMR (101 MHz, CDCl3): δ 165.9, 138.2, 137.7, 135.4, 133.8, 133.3, 133.1, 130.3,130.2, 130.0, 128.6, 128.5, 128.5, 128.2, 128.1, 127.9, 127.0, 126.3, 126.0, 125.9,99.7, 85.6, 81.1, 77.9, 77.4, 76.2, 76.0, 73.9, 71.9, 68.4, 67.6, 25.1, 15.2 ppm.35 GAR-P04580WO13 Application (final).docx 66 Ethyl 4-O-benzoyl-2,6-bis-O-benzyl-3-O-fluorenylmethoxycarbonyl-1-thio-β-D-galactopyranoside (5.03) 5To a w er (7:1,24 mL) , g, . , . q . p on wasstirred at room temperature for 1.5 h protected from light. The mixture was dilutedwith CH2Cl2, washed with aqueous 10% Na2S2O3 and saturated aqueous NaHCO3solution. The organic layer was dried over Na2SO4, filtered, concentrated and the10residue was purified by column chromatography(Hex / EA 9:1 to 3:1) to obtain the titlecompound (1.1 g, 2.2 mmol, 78%) as a colorless solid. Rf = 0.35 (Hex:EA 3:1). To asolution of 4-OH-sugar (1.1 g, 2.2 mmol, 1.0 equiv.) and anhydrous pyridine (0.87mL, 10.8 mmol, 5.0 equiv.) in anhydrous CH2Cl2 (15 mL) at 0 °C was addedFmocCl (838 mg, 3.2 mmol, 1.5 equiv.) followed by 4-DMAP (13 mg, 0.11 mmol, 0.0515 equiv.) and the reaction mixture was stirred for two hours at 0 °C. Aqueous citric acid solution (10 mL) was added and the mixture was allowed to warm up to roomtemperature. The aqueous phase was extracted with CH2Cl2 and the combinedorganic phase was dried over Na2SO4, filtered and concentrated. The title compound(1.2, 1.6 mmol, 76%) was obtained as a white solid after purification by column20 chromatography (Hex / EtOAc = 19:1 to 3:1). Rf = 0.5 (Hex:EA 3:1).[α]D 14.29 cm-1 (c 1, CHCl3).IR (film): 3066, 2927, 2869, 1750, 1726, 1603, 1497, 1451, 1388, 1274, 1246, 1096,1070, 1026, 984, 907, 758, 737, 697 cm-1.25 HRMS (QToF): Calcd forC44H42O8SNa [M + Na]+ 753.2493; found 753.2518.1H NMR (400 MHz, CDCl3): δ 8.10 – 8.03 (m, 2H), 7.76 (ddt, J = 7.7, 1.9, 0.9 Hz,2H), 7.63 (d, J = 7.4 Hz, 1H), 7.60 – 7.52 (m, 2H), 7.49 (t, J = 7.8 Hz, 2H), 7.44 –7.31 (m, 4H), 7.31 – 7.12 (m, 10H), 5.90 (dd, J = 3.4, 1.1 Hz, 1H), 5.00 (dd, J = 9.6,3.4 Hz, 1H), 4.88 (d, J = 10.5 Hz, 1H), 4.71 (d, J = 10.5 Hz, 1H), 4.66 – 4.56 (m, 2H),30 4.39 (d, J = 12.0 Hz, 1H), 4.31 (t, J = 7.4 Hz, 1H), 4.19 (dd, J = 10.3, 8.3 Hz, 1H),3.98 (td, J = 6.4, 1.1 Hz, 1H), 3.81 (t, J = 9.7 Hz, 1H), 3.59 (ddd, J = 33.9, 9.6, 6.4 Hz,2H), 2.93 – 2.74 (m, 2H), 1.37 (t, J = 7.4 Hz, 3H) ppm.13C NMR (101 MHz, CDCl3): δ 165.77, 154.36, 143.97, 143.20, 141.42, 141.29,137.75, 137.57, 133.52, 130.26, 129.56, 128.62, 128.47, 128.28, 127.99, 127.97,35 127.94, 127.87, 127.85, 127.31, 127.23, 125.67, 125.34, 120.10, 85.56, 78.91, 76.29,75.97, 75.90, 73.69, 70.48, 68.54, 68.03, 46.78, 25.37, 15.21 ppm.GAR-P04580WO13 Application (final).docx 67 Example A.3: Preparation of Glucose Building Block 5.05 5 Scheme 3. Synthetic route to α-glucose building block 5.05. Ethyl 2-O-benzyl-4,6-O-[(S)-phenylmethylene]-1-thio-β-D-glucopyranoside (5.16a) 10 Tetrabutylammonium hydrogen sulfate (2.2 g, 6.4 mmol, 0.5 equiv.), benzyl bromide(1.68 mL, 14.1 mmol, 1.1 equiv., filtered using a short aluminium oxide column beforeuse) and 5% aqueous NaOH (33 mL) was added to a stirred solution of ethyl 4,6-O- benzylidene-1-thio-β- D-glucopyranoside (4.0 g, 12.8 mmol, 1.0 equiv.) in CH2Cl2 (30015 mL). The mixture was heated to 45 °C and was stirred for 8 h. The mixture wasallowed to cool down to room temperature and the organic phase was separated fromthe aqueous phase. The aqueous phase was extracted with CH2Cl2 (2 x 100 mL) andthe combined organic phase was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated. 3-OH-galactose 5.16a (2.6 g, 6.5 mmol, 50%) was20obtained as a colorless solid after purification by column chromatography (SiO2, Toluene / EtOAc = 95:5 to 9:1). All spectra are in accordance with literature spectra. Rf = 0.42 (Toluene / EtOAc 9:1).[α]D 24.1 cm-1 (c 1, CHCl3).IR (film): 3066, 2962, 2884, 1761, 1722, 1602, 1453, 1406, 1335, 1266, 1248, 1199,25 1135, 1061, 1027, 998, 916, 805, 753, 700 cm-1. HRMS (QToF): Calcd for C31H33ClO7SNa [M + Na]+ 607.1528; found 607.1539.1H NMR (400 MHz, CDCl3): δ 7.54 – 7.28 (m, 10H), 5.52 (s, 1H), 4.87 (dd, J =68.7, 10.8 Hz, 2H), 4.57 (d, J = 9.8 Hz, 1H), 4.35 (dd, J = 10.4, 4.9 Hz, 1H), 3.89 (t, J= 8.8 Hz, 1H), 3.76 (t, J = 10.2 Hz, 1H), 3.56 (d, J = 9.3 Hz, 1H), 3.45 (d, J = 5.0 Hz,30 1H), 3.38 (dd, J = 9.8, 8.3 Hz, 1H), 2.87 – 2.68 (m, 2H), 1.34 (t, J = 7.5 Hz, 3H) ppm.GAR-P04580WO13 Application (final).docx 68 Ethyl 3-O-b nz l24bi Ob nz l1thi βD l r n id (518) 5 OH-galactose 5.16a (2.6 g, 6.5 mmol, 1.0 equiv.) was dissolved in pyridine (30 mL)and the solution was cooled to 0 °C. Benzoyl chloride (2.26 mL, 19.4 mmol, 3.0equiv.) was added under an argon atmosphere. The reaction mixture was allowed to10 warm up to room temperature and was stirred for 16 h. The reaction was quenched byaddition of water and the aqueous layer was extracted with ethyl acetate (3 x 100mL). The combined organic phase was washed with 1.0 M HCl and brine, dried overNa2SO4, filtered and concentrated. Compound 5.17 (3.1 g, 6.1 mmol, 95%) wasobtained as a colorless oil after purification by column chromatography(Hex / EtOAc =159:1 to 3:1). Rf= 0.29 (Hex / EtOAc 9:1). Compound 5.17 (1.0 g, 2.0 mmol, 1.0equiv.)was co-evaporated by anhydrous toluene and dried for 2 h at high vacuum. Then, itwasdissolved in anhydrous CH2Cl2(25 mL) and the mixture was stirred over activated molecular sieves (3 Å-AW) for 30 minutes at room temperature. The mixturewas cooled to 0 °C and BH3 (1 M solution in THF, 9.9 mL, 9.9 mmol, 5.0 equiv.) and20 TMSOTf (53 µL, 0.29 mmol, 0.15 equiv.) were added dropwise. The mixture wasallowed to warm up to room temperature andstirred under argon atmosphere for 4 h.Et3N (1 mL) was added followed by MeOH until the evolution of H2 ceased. The mixture was concentrated and co-evaporated with MeOH (3 x 30mL). 6-OH-sugar5.18 (805 mg, 1.6 mmol, 80%) was obtained as a white solid after purification by25 column chromatography (Hex:AcOEt 3:1). Rf = 0.18 (Hex: AcOEt 3:1).HRMS (QToF): Calcd for C29H32O6SNa [M + Na]+ 531.1812; found 531.1830.1H NMR (600 MHz, CDCl3): δ 8.02 – 7.97 (m, 2H), 7.61 – 7.55 (m, 1H), 7.48 – 7.4130 (m, 2H), 7.20 – 7.07 (m, 10H), 5.58 (t, J = 9.2 Hz, 1H), 4.79 (d, J = 10.7 Hz, 1H),4.62 (d, J = 9.7 Hz, 1H), 4.55 (s, 2H), 4.54 (d, J = 10.7 Hz, 1H), 3.92 (dd, J = 12.2,2.6 Hz, 1H), 3.80 – 3.72 (m, 2H), 3.54 – 3.47 (m, 2H), 2.84 – 2.73 (m, 2H), 1.33 (t, J= 7.5 Hz, 3H) ppm.13C NMR (151 MHz, CDCl3): δ 165.6, 137.4, 133.3, 130.1, 129.9, 128.6, 128.5, 128.4,35128.1,127.9, 85.4, 79.5, 79.2, 78.0, 75.7, 75.1, 74.8, 62.0, 25.6, 15.3 ppm. GAR-P04580WO13 Application (final).docx 69 Ethyl 3-O-benzoyl-2,4-bis-O-benzyl-6-O-(2-chloroacetyl)-1-thio-β-D- glucopyranoside (5.05) 5 To a solution of 6-OH-sugar 5.1 ol, 1.0 equiv.) and anhydrouspyridine (1.19 mL, 14.8 mmol, 5.0 s CH2Cl2 (20 mL) at -20 °C wasaddedchloroacetyl chloride (0.47 mL, 5.9 mmol, 2.0 equiv.). The reaction was stirred for 10 min, aqueous citric acid solution (2 mL) was added and the mixture was allowed10 to warm up to room temperature. Water was added and the aqueous phase wasextracted with CH2Cl2 (3 x 50 mL). The combined organic phase was dried over Na2SO4, filtered and concentrated. The title compound 5.05 (1.4 g, 2.4 mmol, 81%)was ob ography(Hex:Ac15 Rf = 0.4 [α]D 24.1 cm-1 (c 1, CHCl3).IR (film): 3066, 2962, 2884, 1761, 1722, 1602, 1453, 1406, 1335, 1266, 1248,20 1199, 1135, 1061, 1027, 998, 916, 805, 753, 700 cm-1.HRMS (QToF): Calcd for C31H33ClO7SNa [M + Na]+ 607.1528; found 607.1539.1H NMR (600 MHz, CDCl3): δ 8.05 – 8.00 (m, 2H), 7.62 – 7.56 (m, 1H), 7.46 (t, J =7.8 Hz, 2H), 7.20 (dd, J = 4.9, 1.9 Hz, 3H), 7.12 (dq, J = 5.5, 3.0 Hz, 7H), 5.59 (t, J =8.8 Hz, 1H), 4.79 (d, J = 10.7 Hz, 1H), 4.64 – 4.51 (m, 3H), 4.48 – 4.43 (m, 2H), 4.2925 (dd, J = 11.9, 4.6 Hz, 1H), 4.03 (q, J = 14.8 Hz, 2H), 3.68 (t, J = 6.4 Hz, 2H), 3.53 (t, J= 9.4 Hz, 1H), 2.77 (dtt, J = 20.1, 12.6, 7.4 Hz, 2H), 1.33 (t, J = 7.4 Hz, 3H) ppm.13C NMR (151 MHz, CDCl3): δ 167.1, 165.6, 137.3, 137.0, 133.4, 129.9, 128.7, 128.6,128.5,128.5, 128.4, 128.3, 127.9, 85.4, 79.3, 78.1, 76.5, 75.7, 75.1, 74.7, 64.8, 40.9, 25.6, 15.2 ppm. 30 Example A.4: Automated Glycan Assembly of P. gingivalis LPS fragments5-Amino-pentyl α-D-glucopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→3)-2-35 acetamido-2- deoxy-β-D-galactopyranosyl-(1→3)-α-D-galactopyranoside (3)GAR-P04580WO13 Application (final).docx 68

[0013] Ethyl 3-O-benzoyl-2,4-bis-O-benzyl-1-thio-p-D-glucopyranoside (5.18)

[0014] OH-galactose 5.16a (2.6 g, 6.5 mmol, 1.0 equiv.) was dissolved in pyridine (30 mL) and the solution was cooled to 0 °C. Benzoyl chloride (2.26 mL, 19.4 mmol, 3.0 equiv.) was added under an argon atmosphere. The reaction mixture was allowed to warm up to room temperature and was stirred for 16 h. The reaction was quenched by addition of water and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic phase was washed with 1.0 M HCI and brine, dried over Na2SO4, filtered and concentrated. Compound 5.17 (3.1 g, 6.1 mmol, 95%) was obtained as a colorless oil after purification by column chromatography (Hex / EtOAc = 9:1 to 3:1 ). Rr = 0.29 (Hex / EtOAc 9:1 ). Compound 5.17 (1.0 g, 2.0 mmol, 1.0 equiv.) was co-evaporated by anhydrous toluene and dried for 2 h at high vacuum. Then, it was dissolved in anhydrous CH2CI2 (25 mL) and the mixture was stirred over activated molecular sieves (3 A-AW) for 30 minutes at room temperature. The mixture was cooled to 0 °C and BH3 (1 M solution in THF, 9.9 mL, 9.9 mmol, 5.0 equiv.) and TMSOTf (53 pL, 0.29 mmol, 0.15 equiv.) were added dropwise. The mixture was allowed to warm up to room temperature and stirred under argon atmosphere for 4 h. Et3N (1 mL) was added followed by MeOH until the evolution of H2 ceased. The mixture was concentrated and co-evaporated with MeOH (3 x 30 mL). 6-OH-sugar 5.18 (805 mg, 1.6 mmol, 80%) was obtained as a white solid after purification by column chromatography (Hex:AcOEt 3:1 ).

[0015] Rr= 0.18 (Hex: AcOEt 3:1 ).

[0016] HRMS (QToF): Calcd for C29H32O6SNa [M + Na]+531 .1812; found 531.1830.

[0017] 1H NMR (600 MHz, CDCI3): 5 8.02 - 7.97 (m, 2H), 7.61 - 7.55 (m, 1 H), 7.48 - 7.41 (m, 2H), 7.20 - 7.07 (m, 10H), 5.58 (t, J = 9.2 Hz, 1 H), 4.79 (d, J = 10.7 Hz, 1 H), 4.62 (d, J = 9.7 Hz, 1 H), 4.55 (s, 2H), 4.54 (d, J = 10.7 Hz, 1 H), 3.92 (dd, J = 12.2, 2.6 Hz, 1 H), 3.80 - 3.72 (m, 2H), 3.54 - 3.47 (m, 2H), 2.84 - 2.73 (m, 2H), 1 .33 (t, J = 7.5 Hz, 3H) ppm.

[0018] 13C NMR (151 MHz, CDCI3): 5 165.6, 137.4, 133.3, 130.1 , 129.9, 128.6, 128.5, 128.4, 128.1 , 127.9, 85.4, 79.5, 79.2, 78.0, 75.7, 75.1 , 74.8, 62.0, 25.6, 15.3 ppm. 71 Protected 3 (22 mg, 0.011 mmol, crude yield: 81%) was obtained as a colorless oilafter photocleavage from solid support following Method A-1. Deprotection of 3 5followingMethod C and D and purification by reverse-phase HPLC (Method E-1, tR =18.8 min) afforded deprotected compound 3 (1.1 mg, 0.002 mmol, 11%) as a whitesolid after lyophylization. 1H NMR (700 MHz, D2O): δ 4.97 – 4.92 (m, 1H), 4.85 – 4.80 (m, 1H), 4.79 (s, 1H),4.63 (d, J = 8.2 Hz, 1H), 4.10 (s, 1H), 4.01 – 3.55 (m, 19H), 3.49 – 3.42 (m, 2H), 3.4310 – 3.35 (m, 2H), 2.94 – 2.89 (m, 2H), 1.95 (s, 3H), 1.64 – 1.57 (m, 4H), 1.40 – 1.34 (m,2H), 1.27 (d, J = 6.2 Hz, 3H) ppm. 13C NMR (176 MHz, D2O): δ 174.9, 102.5, 102.0,99.7, 98.4, 81.0, 79.0, 75.0, 72.7, 70.7, 70.5, 69.3, 68.7, 68.4, 67.8, 67.3, 61.2, 60.9,60.1, 51.8, 39.4, 28.1, 26.6, 22.4, 22.2, 16.9 ppm. HRMS (QToF): Calcd for C31H57N2O20 [M + H]+ 777.3499; found 777.3508.15 5-Aminopentyl-α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside (1) 1 GAR-P04580WO13 Application (final).docx 72 l 510,,15 GAR-P04580WO13 Application (final).docx 73 5 10 GAR-P04580WO13 Application (final).docx 74 l5R = 19.4 min) afforded deprotected compound 4 (1.8 mg, 0.002 mmol, 18%) as a whitesolid after lyophylization. 1H NMR (700 MHz, D2O): δ 5.01 (d, J = 3.9 Hz, 1H), 4.91 (d, J = 3.9 Hz, 1H), 4.76– 4.74 (m, 1H), 4.60 (d, J = 8.5 Hz, 1H), 4.19 – 4.14 (m, 2H), 3.98 (dd, J = 11.3, 3.510 Hz, 1H), 3.94 – 3.60 (m, 18H), 3.57 – 3.48 (m, 3H), 3.44 (t, J = 9.4 Hz, 1H), 2.96 (t, J= 7.7 Hz, 2H), 1.99 (s, 2H), 1.68 – 1.56 (m, 4H), 1.41 (d, J = 7.9 Hz, 2H), 1.33 (d, J =6.3 Hz, 3H) ppm. 13C NMR (176 MHz, D2O): δ 175.1, 103.2, 99.7, 99.4, 98.1, 81.1, 79.1, 74.9, 72.9,71.3, 70.7, 70.5, 70.4, 69.2, 69.1, 69.0, 67.6, 67.5, 67.4, 65.1, 60.9, 52.6, 39.2,15 28.0, 26.5, 22.3, 22.2, 16.6 ppm.HRMS (QToF): Calcd for C31H57N2O20 [M + H]+ 777.3499; found 777.3501.20 5-Aminopentyl-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranosyl-(1→6)-α-D-glucopyranoside (5)GAR-P04580WO13 Application (final).docx 5-Aminopentyl-2-acetamido-2-deoxy-p-D-galactopyranosyl-(1— >3)-a-D- galactopyranosyl-(1 >6)-a-D-glucopyranosyl-(1 >4)-a-L-rhamnopyranoside (4) 76 l 51015 Protected 11 (8 mg, 0.012 mmol, crude yield: 87%) was obtained as a colorless oil20 after photocleavage from solid support following Method A-1. Deprotection of 11followingMethod C and D and purification by reverse-phase HPLC (Method E-1, tR=13.5 min)afforded deprotected compound 11 (1.2 mg, 0.004 mmol, 18%) as a white solid after lyophylization. 1H NMR (700 MHz, D2O): δ 4.95 (d, J = 3.4 Hz, 1H), 3.98 (d, J = 3.2 Hz, 1H), 3.93 (t, J25 = 6.2 Hz, 1H), 3.87 – 3.81 (m, 2H), 3.78 – 3.72 (m, 3H), 3.54 (dt, J = 10.0, 6.2 Hz,1H), 3.01 (t, J = 7.6 Hz, 2H), 1.75 – 1.62 (m, 4H), 1.53 – 1.42 (m, 2H) ppm.13C NMR (176 MHz, D2O): δ 98.2, 70.9, 69.5, 69.3, 68.3, 67.8, 61.3, 39.4,28.0, 26.5, 22.4 ppm.HRMS (QToF): Calcd for C11H24NO6 [M + H]+ 266.1598; found 266.1726.GAR-P04580WO13 Application (final).docx

[0019] 5 5 P l a foR 10= 12.8 min)afforded deprotected compound 8 (0.9 mg, 0.003 mmol, 25%) as a white solid after lyophylization. 1H NMR MH D 4 2 H 1H 12 24 H 1H,J15 ,20 25 GAR-P04580WO13 Application (final).docx 78 5-Amino-pentyl-2-acetamido-2-deoxy α-D-galactopyranoside (10) 10 Compound 10 was prepared from compounds 5.01 and 5.02 according to the same5 procedure as used for compound 8 described above.5-Aminopentyl-2-acetamido-2-deoxy-β-D-galactopyranosyl-(1→3)-α-D- galactopyranoside (6) 10 15 Protected 6 (11 mg, 0.009 mmol, crude yield: 67%) was obtained as a colorless oil after photocleavage from solid support following Method A-1. Deprotection of 6 followingMethod C and D and purification by reverse-phase HPLC (Method E-1, tR=15.6 min)afforded deprotected compound 6 (1.1 mg, 0.002 mmol, 17%) as a white solid after lyophylization.20 1H NMR (700 MHz, D2O): δ 4.92 (d, J = 3.8 Hz, 1H), 4.65 (d, J = 8.4 Hz, 1H), 4.20(d, J = 3.2 Hz, 1H), 3.97 – 3.86 (m, 5H), 3.83 – 3.71 (m, 6H), 3.70 – 3.65 (m, 1H),3.54 (dt, J = 9.9, 6.2 Hz, 1H), 3.01 (t, J = 7.6 Hz, 2H), 2.04 (s, 3H), 1.74 – 1.63 (m,GAR-P04580WO13 Application (final).docx 79 4H), 1.53 – 1.42 (m, 2H) ppm. 13C NMR (176 MHz, D2O): δ 175.2, 103.1, 98.4, 79.0,75.0, 70.8, 70.5, 69.3, 67.8, 67.3, 61.2, 61.0, 52.7, 39.4, 28.1, 26.5, 22.4, 22.3 ppm.H +5 2 10 GAR-P04580WO13 Application (final).docx 80 Protected 2 (16 mg, 0.01 btained as a colorless oil after photocleavage from A-1. Deprotection of 2followingMethod C and se HPLC (Method E-1, tR5= 17.4 min)afforded depr 02 mmol, 15%) as a white solid after lyophylization. 1H NMR (700 MHz, D2O): δ 4.83 (d, J = 3.9 Hz, 1H), 4.80 (s, 1H), 4.65 (d, J = 8.5Hz, 1H), 4.11 (d, J = 3.4 Hz, 1H), 3.96 (dd, J = 11.0, 8.5 Hz, 1H), 3.89 – 3.56 (m,14H), 3.46 (dt, J = 10.1, 6.3 Hz, 1H), 3.36 (t, J = 9.7 Hz, 1H), 2.93 (t, J = 7.6 Hz, 2H),10 1.97 (s, 3H), 1.61 (dt, J = 12.3, 6.1 Hz, 4H), 1.38 (q, J = 8.7 Hz, 2H), 1.20 (d, J = 6.2Hz, 3H) ppm. 13C NMR (176 MHz, D2O): δ 174.9, 102.5, 102.3, 98.4, 79.0, 78.6, 75.0, 71.9, 70.5,7p155 g 20 GAR-P04580WO13 Application (final).docx 81 Protected 7 (12 mg, 0.010 mmol, crude yield: 76%) was obtained as a colorless oil after photocleavage from solid support following Method A-1. Deprotection of 7followingMethod C and D and purification by reverse-phase HPLC (Method E-1, tR=17.4 min)afforded deprotected compound 7 (0.56 mg, 0.013 mmol, 10%) as a 5 white solid after lyophylization. 1H NMR (700 MHz, D2O): δ 4.93 (d, J = 3.7 Hz, 1H), 4.88 (d, J = 3.8 Hz, 1H), 3.96,,10 , 15 20 f 1(25 ( GAR-P04580WO13 Application (final).docx 82 3.40 (m, 3H), 3.01 (t, J = 7.6 Hz, 2H), 1.76 – 1.61 (m, 4H), 1.53 – 1.41 (m, 2H), 1.31(d, J = 6.3 Hz, 3H), 1.30 (d, J = 6.2 Hz, 3H), 1.28 (d, J = 6.2 Hz, 3H) ppm.13C NMR (176 MHz, D2O): δ 102.2, 100.9, 98.4, 72.1, 72.1, 72.0, 70.2, 70.1, 70.0,69.8, 69.3, 69.1, 68.8, 67.7, 39.4, 28.0, 26.6, 22.4, 16.6 ppm.5 HRMS (QToF): Calcd for C23H44NO13 [M + H]+ 542.2807; found 542.2811.Example A.5: Synthesis and characterization of conjugates10 General procedure synthesisThe saccharide (1: 0.7 mg; 2: 0.8 mg) was dissolved in 200 µL DMSO, 25 µL Pyridineand 10 µL Triethylamine were added. 6.5 equivalent of (4-nitrophenyl) adipate linker inDMSO were added to the saccharide solution. After 3 h of stirring, the reactionmixture was frozen in liquid nitrogen and subsequently lyophilized to give a crude15 white solid. The residue was washed with chloroform (5x 100 µL) and DCM (3x 1 µL)to remove excess of bis (4- nitrophenyl) adipate. It was checked by TLC that allexcess linker was washed away and no glycan dissolved. 350 µL of water wereadded to an 10k Amicon filter and centrifuged at 10000 rpm for 8 min to wet the filter.Then CRM197 was transferred into the Amicon 10k filter (180 µL 1 mg) and the tube2025 (2 x 30 µL) and added to reaction solution. The reaction was stirred slowly for 24 h. The solution was transferred onto an Amicon 10K filter and the reaction vial was30 s35fl - methylenebisacrylamide mixture), polymerized by the addition of TEMED and 10% GAR-P04580WO13 Application (final).docx 83 (w / v) ammonium peroxodisulfate, were used. 1 µg of glycoconjugate and CRM197samples were dissolved in SDS-PAGE loading buffer (250 mM Tris (pH 6.8), 5 %(v / v) beta-mercaptoethanol, 10 % (w / v) SDS, 0.4% bromophenol blue, 50 % (v / v)glycerol) and were loaded. 4µL of PageRuler Plus Prestained Protein Ladder 105 to 250 kDa (Thermo Scientific) was used. The samples were run at 80 V and 25mAfor 15 min and then at 120 V and 25 mA for 90 min and stained with 0.5 % (w / v)Coomassie Brilliant Blue R-250 for 30 min.Mass spectra were acquired with an Autoflex Speed MALDI-TOF system (Bruker10 Daltonics; Bremen, Germany). Samples were spotted using the dried droplet technique with 2,5- dihydroxyacetophenone (DHAP) as matrix on MTP 384 groundsteel target plates (Bruker Daltonics). The mass spectrometer was operated in linear positive mode. Mass spectra were acquired over an m / z range from 30,000 to 210,000 and data was analyzed with the FlexAnalysis software provided with the15 instrument. Conjugation was checked by MALDI-TOF-MS and SDS-PAGE (Figure 5). The results showed that 1 and 2 were successfully conjugated to CRM197. The average loadingwas 4.51 units and 7.72 units per protein monomer.20 GAR-P04580WO13 Application (final).docx 84 O2N O OHOHHOOH1. O O O O O O O Et3N, DMSO, pyridine NO2NH OH O O NH2r.t. HOO (CH2)5HO OH2. CRM1970.1 M NaPi pH 8.0r.t. OHOHHOOHO O O CRM197 O O NH OH HOOO N O H O HO OHconjugate CRM -~7-8 197 trisaccharide 2B. Biological Evaluation 5 Example B.1: Mice immunization and generation of polyclonal sera Immunization The immunizations were approved by Landesamt für Gesundheit und Soziales Berlin,10 Germany (Approval ID: G 0329 / 18). 8 weeks old C57BL / 6NRj mice (Janvier, Le Genest-Saint_Isle, France) were housed at Bundesinstitut für Risikobewertung,Berlin, Germany in groups of five animals in individually ventilated cages (Tecniplast,Hohenpeißenberg, Germany) under specific pathogen-free conditions. Housing and experiments were in accordance with institutional guidelines and with the regulations15 of the Federation of European Laboratory Animal Science Associations (FELASA). Mice were immunized subcutaneously (s.c.) with 1µg of glycoconjugate per injection. The glycoconjugates, together with Alum adjuvant, were diluted in sterile PBS to afinal volume of 100 µL per dose. The animals were immunized on day 0 (primaryimmunization) and boosted on days 14, 28, and final boosting on day 196. Blood 20 (max.80µL) and saliva were collected every two weeks. The mice were fixed with on hand and a swap was used to collect the saliva and was afterwards centrifuged at 400 g for 5 min. After coagulation at room temperature, serum was separated bycentrifugation at 2,000 g for 10 min. The sera and saliva were frozen at -20°C untilfurther usage. GAR-P04580WO13 Application (final).docx 85 Scheme 4. Immunization Schedule. Three groups of five C57 / BL / 6NRj mice 5 were immunized with either 1-CRM197, 2-CRM197or CRM197. The primary immunization was followed by two boosts with 14 days interval. A final boost was conducted at day 196. Blood and saliva were collected every two weeks. 10 Hybridoma Generation -f15 i.-,20 ri25 r mg / mL Gentamycin, 1% Penicillin / Streptomycin, 10% FCS, 1% Non-Essential Amino Acids, 1xHAT (Hypoxanthin / Aminopterin / Thymidin), 1x BM-Condimed H1 supplement). 200 µL / well of cells were plated onto 96-well flat-bottom plates andincubated at 37°C and 5% CO2Binding to synthetic glycans was checked via Glycan GAR-P04580WO13 Application (final).docx 86 tt510 t l 15 i mmobilized on glass microarray slides. The slides were then quenched, blocked with1% BSA-PBS, and stored at 4°C until use. A FlexWell 64 grid was attached, and theslides were incubated with mice sera diluted 1:100 or with pooled saliva samplesdiluted 1:5 in 1% BSA-PBS (w / v) or or monoclonal antibodies (10 µg / mL) in a20 humidification chamber for 1 hour at 37 °C. After washing three times with PBST, slides were incubated with fluorescently labeled secondary antibodies (Alexa Fluor®488 AffiniPure Goat Anti-Mouse IgG, Fcγ fragment specific, JacksonImmunoResearch, Goat anti-Mouse IgM (Heavy chain) Secondary Antibody, Alexa Fluor™ 647, invitrogen, Goat Anti-Mouse IgA alpha chain (DyLight® 594), abcam)25 each diluted 1:400 in blocking buffer.Slides were incubated for 1 hour at 37 °C in a humidification chamber, washed threetimes with PBST, rinsed with deionized water, and dried by centrifugation.Fluorescence signals were measured with a Genepix 4300A device (Molecular30 Devices, Sunnyvale, CA, USA). The photomultiplier tube (PMT) voltage was adjusted to avoid oversaturation of thesignals. Data were analyzed using GenePix Pro 7 software (Molecular Devices,Sunnyvale, CA, USA).GAR-P04580WO13 Application (final).docx 87 Scheme 5: Microarray printing pattern of P. Gingivalis glycans to test mice sera and saliva samples, glycans 0.1 mM printing concentration, proteins 100 µg / mL. PB – Printing buffer. PG: peptidoglycan, mIgG: murine IgG isotype5 control, hIgG: human IgG isotype control, mIgM: murine IgM, hIgM: human IgM, LPS: commercial LPS , CRM: CRM197 P. gingivalis W50 cultureP. gingivalis W50 (ATCC-53978) bacteria were cultured for 5 to 7 days on Columbia10 Blood agar plates (VWR, Belgium) under anaerobic conditions. For liquid cultures,bacteria were cultured overnight in Supplemented Tryptic Soy Broth (ATCC medium 2722). Anaerobic conditions were created in an anaerobic culture jar supplemented with a 2.5 l Thermo Scientific™ Oxoid™ AnaeroGen™ pack (Thermo FisherScientific). 100 ml of ATCC Medium 2722 is composed of 30.0 g Tryptic Soy Broth,15 5.0 g Yeast Extract, 0.5g L-cysteine hydrochloride, 1.0 mL Hemin stock (5µg / mL),0.5 g Hemin, 1.74 g K2HPO4, 0.2 mL Vitamin K3 stock (5mg / mL; final concentration1.0 µg / mL) and 100 mL distilled water. The medium was autoclaved at 121°C afterpreparation.20 Bacterial ELISA with P. gingivalis W50 and commercial LPSBacteria were cultured overnight in Supplemented Tryptic Soy Broth to obtaindifferent ODs. Bacteria were grown to an OD of 0.7 (~9.4 x 1010 cfu) and centrifugedat 3000 g during 5 min. Supernatant was discarded. Bacteria were washed threeGAR-P04580WO13 Application (final).docx 88 times with PBS and were afterwards diluted in 10 ml of carbonate bicarbonate coating buffer. High-binding flat bottom ELISA plates (Corning) were coated with 100 µl of diluted bacteria or commercial LPS (InvivoGen, Cat.# tlrl-pglps) (10 µg / mL)and were incubated at 4 °C overnight. ELISA plates were washed 3 times with PBST. 5 Sera of day 56 after immunization was diluted 1:100 in PBS / BSA. 50 µl of serum dilution or monoclonal antibodies (0.005, 0.05, 0.5, 5, 50, 100, and 200 µg / mL) intriplicates were pipetted into corresponding wells and incubated at RT for 2 hours.Plates were washed 3 times with PBST.10 Per well 50 µl of goat- anti mouse IgG HRP antibody (Dianova) was added at adilution of 1:10000 and incubated for 3 hours. Plates were washed 3 times withPBST. 100 µl of substrate TMB was added to each well. After 10 min the reactionwas stopped by adding H2SO4. Theabsorbance was read at 450 nm in aCLARIOstar Plus plate reader (BMG Labtech). 15 Statistical AnalysisGraphing and statistical analysis (one sample t-test) were performed using GraphPadPrism 9.3.1. 20 Glycan Microarray Experiments (human sera, human saliva)The rapid synthesis of a library of LPS fragments by AGA in combination withfollowing high throughput glycan microarray studies is a fast and efficient tool to identify an active epitope. The determination of the active epitope is essential for the 25 design of conjugate vaccines, because the identified antigen will be responsible for the generation of specific antibodies after immunization in order to produce a protective immune response. In previous studies, P. gingivalis infected patientsshowed to form IgG and IgA antibodies in blood and saliva against pathogen-specific antigens.30 Here, human sera and saliva from P. gingivalis infected patients were used toscreen antibodies against the synthetic glycan library 1-11 to determine whether LPSfragments are potential leads for vaccine development. Samples were taken from a pool of patients at the Charité Zahnklinik (provided by Prof. Dr. Henrik Dommisch). The dental status of three groups of patients was 35 defined as: healthy (20 patients, no clinical indications for CP), infected (16 patients, CP stage III or stage IV) and recovered from CP (six patients). Recovered patients were treated from CP stage III or stage IV at the Charité Zahnklinik by resective and regenerative surgery and execution of two to four professional dental cleanings per year. GAR-P04580WO13 Application (final).docx 89 The synthesized LPS fragments of P. gingivalis were immobilized at NHS-activatedcarboxyl-functionalized glass slides in triplicates (Figure 10 A, B). Additionally, a positive glycan control containing the α(1→2)-trirhamnose (5.06) was used in the 5 assay, because most humans develop antibodies against this pathogen-associated glycan Results Immunization with the glycoconjugate vaccines lead to the development of glycan 10 specific antibodies in sera of mice. Mice immunized with 1-CRM197 developed antibodies binding to 1 on the glycan array. Mice immunized with 2-CRM197developed an immune response against 2. IgG antibody levels started to increase 28 days after immunization and stayed at high levels throughout the course of theexperiment (Figure 6 A). Antibody levels against 2 in mice immunized with 2-CRM19715 were in general slightly higher than levels against 1 in mice immunized with 1-CRM197. This could be due to higher loading of 2 antigens onto CRM197. In additionto that, all mice developed an antibody response against CRM197. Control miceimmunized with CRM197 only developed stable antibody responses against CRM197and did not show immune responses against the tested synthetic structures.20 The IgM response against 2 peaked at day 14 with still relatively high IgM levels onday 28. IgM-responses against 1 and CRM197 remained at low levels (Figure 6 B).Serum IgA levels were in general very low with a signal below a MFI of 400 (Figure 6 C). The conjugate could hence not induce strong serum IgA immune responses25 against 1 and 2.Since P. gingivalis primarily affects the oral cavity, antibody titers against the synthetic structures in saliva were tested on the glycan array. Saliva of all 5 mice of each group were pooled and diluted. High mucosal IgG responses against 2 could bedetermined in the 2-CRM197 group from day 70 on after immunization (Figure 7 A).30 1-CRM197 and PBS-CRM197 did not induce an IgG immune response against 1 orCRM197 respectively. IgM and IgA antibodies were very low across all groups insaliva samples (Figure 7 B and 7 C). Mucosal IgA formation could not be observed onthe glycan array. However, antibody titers could be too low to be detected, since onlyvery few microliters of saliva could be recovered per mouse. 35 Binding of mice sera and mice saliva samples to synthetic glycans was shown byglycan array. A bacterial ELISA was performed to show binding to native LPSstructures on P. gingivalis W50 as well. Figure 9 shows that serum-IgG of miceimmunized with 1-CRM197 are binding to P. gingivalis W50. Antibodies targeting 140 generated by the hybridoma technology were also binding to P. gingivalis W50.GAR-P04580WO13 Application (final).docx 90 This is consistent with the previous findings that IgG in serum of patients infected with P. gingivalis binds to synthetic 1. Binding to native structures is especiallyimportant for further vaccine development, since the epitopes can be hidden or 5 presented in a different way on bacteria than on glycan arrays. Immunization with the 1-CRM197 glycoconjugate vaccine induces serum IgG-antibodies that are capable of binding bacterial LPS. In addition to that, the monoclonal antibodies generated against 1 are binding to P. gingivalis on the array.10 The 2-CRM197 glycoconjugate vaccine candidate did not induce antibody binding tonative bacterial LPS. The normalized fluorescence was in a similar range as bindingof sera from mice vaccinated with the PBS-CRM197 control. Binding of human sera and human saliva samples to synthetic glycans was shown by15 glycan array. While P. gingivalis was identified in the dental plaque of all patients, thebacterial amount was generally higher for chronic periodontitis patients (mean(cT) of18.52) and recovered patients (mean(cT) of 21.70) compared to healthy individuals (mean(cT) of 24.71, Table 1). 20 Table 1: CT values (PCR) of the three patient groups (dental healthy, chronic periodontitis and recovered from chronic periodontitis). Patients with outlayinghigh antibody-binding in microarray studies are marked in bold. Dental status: Healthy Dental status: CP Dental status: Recovered from CPMean(cT) = 24.71 Mean(cT) = 18.52 Mean(cT) = 21.70Sample cT Sample cT Sample cTP-H-00 21.82 P-I-01 28.14 P-T-01 21.09P-H-01 21.9 P-I-02 23.42 P-T-02 21.95P-H-02 24.3 P-I-03 16.15 P-T-03 22.13P-H-03 25.32 P-I-04 19.9 P-T-04 23.65P-H-04 25.72 P-I-05 18.55 P-T-05 16.15P-H-05 25.08 P-I-06 22.93 P-T-06 25.22P-H-06 24.94 P-I-07 17.62P-H-07 30.85 P-I-08 18.66P-H-08 24.52 P-I-09 17.35P-H-09 22.15 P-I-10 23.54P-H-10 25.74 P-I-11 14.53P-H-11 23.33 P-I-12 19.23P-H-12 24.17 P-I-13 16.71P-H-13 25.25 P-I-14 17.94GAR-P04580WO13 Application (final).docx 91 P-H-14 24.72 P-I-15 16.72P-H-15 25.01 P-I-16 14.51P-H-16 25.04P-H-17 24.76P-H-18 25.96P-H-19 23.59The glycan microarray analysis of human saliva compared to human serum generally showed IgG antibody binding to the same LPS-fragments 5, 3, 9, 7, 4 as well as thepositive control 5.06 (Figure 10 D, E). While only saliva of CP patients with high 5 bacterial load show IgG antibody binding to the listed LPS glycan structures, also serum of healthy and treated individuals contains IgG antibodies against those structures. It is generally known, that human serum contains antibodies against rhamnose structures as well as α-galactose structures, because those units are common motifs at bacterial surfaces. The specific binding of antibodies in saliva of10 chronic periodontitis patients to some LPS-glycan structures is an evidence for theactive mucosal IgG antibody production in the advanced affection of P. gingivalis inCP. IgG antibodies against positive control 5.06 in saliva were also observed inhealthy individuals, but significantly less than in chronic periodontitis patients andrecovered chronic periodontitis patients, which supports this result. Generally, it is15 known, that salivary antibodies reflect both mucosal and systemic immunity. The glycan microarray studies using saliva show a few outlying data points (Figure 11). CP patients I-07, I-09 and I-16 for example have the highest MFI tospecific glycans and at the same time the highest bacterial load according to the low 20 cT value (Table 1) as well as particularly distinct clinical indications for CP including significant damage to the attachment apparatus, deep periodontal lesions and deep intrabony defects. This shows that the stage of periodontitis and bacterial load is proportional to the IgG titer. CP treated patient T-01 also shows IgG binding to specific glycans, while the remaining treated patient group is generally comparable 25 with healthy individuals. Interestingly, the frequent professional dental cleaning was skipped for more than ten months in case of T-01. Therefore, the high IgG titer for T- 01 could be a first sign of a resurgence of the infection, while clinical indications for CP were not visible yet. Further time-dependent screenings on treated patients before and after the professional dental cleaning and after a longer period of time 30 without such cleaning could give an idea about a potential of early diagnosis for high CP risk or CP resurgence using the here described glycan array studies. GAR-P04580WO13 Application (final).docx 92 The epitopes that show binding to IgG antibodies in saliva and blood are generally LPS-fragments with a terminal α(1→3)-rhamnose unit (5, 2 and 9, Figure 12) or aterminal α(1→6)-galactose unit (3, 7 and 11, Figure 13.).5 Figure 12 compares the mean fluorescence intensity (MFI) indicating IgG titer ofbound human IgG antibodies in saliva to terminal α(1→3)-rhamnose LPS-fragments. Interestingly, 2 trisaccharide shows higher IgG antibody binding than 5tetrasaccharide, even though higher molecular weight glycan antigens are known to elicit a better immune response than lower molecular weight fragments. On the other10 hand, 2 trisaccharide shows higher amount of IgG antibody binding than to rhamnosemonomer 9. This indicates, that observed IgG antibody binding to 2 is not onlyattributed to general antibodies against common bacterial rhamnose motifs, but more likely also to the actual LPS-fragment of P. gingivalis. These values, however, have low statistical significance (P ≤ .1), likely due to the different cT values inside each15 group. More significant results would probably be received in a larger CP group (n > 16). Nevertheless, the statistical significance of the stronger IgG binding observed for CP patients to 2 compared to low IgG binding for healthy and recovered patients ishigh (P ≤ .01) and is a clear evidence for the active mucosal IgG antibody productionin the advanced affection of P. gingivalis in CP against 2.20 Figure 13 compares the bound human IgG antibodies in saliva to terminal α(1→6)- galactose LPS-fragments. 1 tetrasaccharide exhibits the strongest IgG interactionobserved in these studies. Conversely, disaccharide 7 and monosaccharide 11 bindsignificantly less IgG (P ≤ .05). This suggests, that all four parts of the LPS repeating25 unit have an impact on the binding to IgG. The antibody binding not just arises from binding of general α(1→6)-galactose antibodies. Furthermore, IgG binding in CP saliva to 1 is significantly higher than in dental healthy patients (P ≤ .05). Thissupports the assumption, that epitope 1 is specific for P. gingivalis. The glycanmicroarray studies show that the order of the four tetrasaccharide fragments 1 and 330 to 5 in the LPS repeating unit of P. gingivalis is important for the binding to IgGantibodies. α(1→6)-Galactose terminal LPS-fragment 1 shows the highest amount ofbound IgG antibodies in this study. As IgA antibodies are the predominant mucosal antibody species, it was also 35 screened for IgA antibody binding (Figure 10 F, G). Here, approximately ten-fold lower MFI for IgA antibody binding was observed, compared to IgG binding. Saliva samples showed stronger binding, which is expectable due to the high IgA content insaliva. Only positive control rhamnose structures 9 and 5.06 as well asα-galactose dimer 7 show significant binding of IgA in saliva and serum – strucuturesGAR-P04580WO13 Application (final).docx 93 that are common for many bacteria. There is also no significant difference observed between CP patients and dental healthy and recovered individuals. Dental healthy individuals actually show slightly higher IgA levels against the common bacteria glycan structures. The screening for IgG antibodies using a fluorescent-labeled 5 secondary antibody (Fc-AF 647) in glycan microarray studies is commonly used to evaluate the immunogenicity of glycans and has already provided reliable results. The screening of IgA antibodies has been included in very few glycan microarray studies. Therefore, little is known on the IgA binding strength, to the immobilizedglycans as well as the competition to IgG binding. However, it was clearly observed10 that IgA does not bind to antigen structures that are specific for P. gingivalis and onlyIgG antibodies seem to be actively produced against 1 in the case of a severe formof CP. GAR-P04580WO13 Application (final).docx 94 Claims 5 1. A saccharide of general formula (I) H–Ux+2–Ux+1–Ux–T–O–L–NH2(I) 10 wherein x is an integer selected from 1 and 3; U1 = U5 = U2 = U6 = ; ,;U3 = U4 = ; –T– represents a bond, –Ux+3–, –Ux+3–Ux+2–, –Ux+3–Ux+2–Ux+1–, or –[Ux+3–Ux+2–Ux+1–Ux]n– with n being an integer selected from 1, 2 and 3; 15 R1represents –H or –PO2–O–CH2CH2–NH2; L represents a linker; or a pharmaceutically acceptable salt thereof.20 2. The saccharide according to claim 1, wherein R1 represents –H.3. The saccharide according to claim 1 or 2, wherein –T– represents a bond or–Ux+3–.25 4. The saccharide according to claim 1 of general formula (III)H–Ux+2–Ux+1–Ux–[Ux+3–Ux+2–Ux+1–Ux]n–O–L–NH2(III) wherein Ux, Ux+1, Ux+2, Ux+3, x, L, and n have the meanings as defined in claim 1. 30 GAR-P04580WO13 Application (final).docx 95 5. The saccharide according to any one of the claims 1 to 4, wherein–L– represents –La–, –La–Le–, –La–Lb–Le–, or –La–Ld–Le– ;–La– represents –(CH2)o–, –(CH2–CH2–O)o–C2H4–, or –(CH2–CH2–O)o–CH2; 5 –Lb– represents –O–, –NH–CO–NH–, –NH–CO–CH2–NH–, –NH–CO–; –Ld– represents –(CH2)q–, –(CH(OH))q–, –(CF2)q–, –(CH2–CH2–O)q–C2H4–, or –(CH2–CH2–O)q–CH2– ;–Le– represents –(CH2)p1–, –(CF2)p1–, –C2H4–(O–CH2–CH2)p1–,–CH2–(O–CH2–CH2)p1– or –(CH2)p1–O–(CH2)p2– ; and10 o, q, p1 and p2 are independently of each other an integer selected from 1, 2, 3,4, 5, and 6. 6. The saccharide according to any one of the claims 1 to 4, wherein–L– represents –(CH2)o– and o is an integer selected from 2, 3, 4, 5, 6, 7 and 8.15 7. The saccharide according to claim 1 selected from5-aminopentyl-α-D-galactopyranosyl-(1→6)-α-D-glucopyranosyl-(1→4)-α-L- rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D-galactopyranoside; 5-aminopentyl-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranoside; and5-aminopentyl-α-L-rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-β-D- galactopyranosyl- (1→3)-α-D-galactopyranosyl-(1→6)-α-D-glucopyranoside.8. A conjugate comprising a saccharide of general formula (I) according to any ofthe claims 1 – 7 covalently linked to an immunogenic carrier through the20 nitrogen atom of the –O–L–NH2group. 9. The conjugate according to claim 8, wherein the immunogenic carrier is a carrierprotein, a P. gingivalis outer membrane protein or a glycosphingolipid.25 10. The conjugate according to claim 8 of general formula (IV)[H–Ux+2–Ux+1–Ux–T–O–L–NH–W]m–IM (IV)wherein m is comprised between 2 and 18; –W– is selected from:, and , GAR-P04580WO13 Application (final).docx

Claims

96 O O O b O ; a represents an integer from 1 to 10; b represents an integer from 1 to 4; IM represents an immunogenic carrier, andUx, Ux+1, Ux+2, Ux+3, x, n and L have the meanings as defined in any one of the5 claims 1 – 7.

11. The conjugate according to claim 8 of general formula (V) 7(V)10O O b O ; a represents an integer from 1 to 10; b represents an integer from 1 to 4; and Ux, Ux+1, Ux+2, Ux+3, x, n and L have the meanings as defined in any one of the15 claims 1 – 7.

12. The conjugate according to claim 9, wherein the glycosphingolipid is (2S,3S,4R)-1-(^-D-galactopyranosyl)-2-hexacosanoylaminooctadecane-3,4-diol.20 13. A pharmaceutical composition comprising at least one saccharide according toany one of the claims 1 – 7 and / or at least one conjugate according any one of theclaims 8 – 12 as an active ingredient together with at least one pharmaceuticallyacceptable adjuvant and / or excipient.25 14. The saccharide according to any one of the claims 1 – 7, the conjugateaccording to any one of the claims 8 – 12, or the pharmaceutical compositionGAR-P04580WO13 Application (final).docx97 according to claim 13 for use in prevention and / or treatment of disease associated with Porphyromonas gingivalis, wherein the disease is periodontal 515.16.10 saccharide according to any one of claims 1 – 7.

17. The monoclonal antibody or the fragment thereof according to claim 16, whereinthe monoclonal antibody has been raised against a conjugate according to any one of claims 8 – 12.15 18. Hybridoma CD4E1F5.

19. An in-vitro method for detecting the presence of Porphyromonas gingivalisbacteria in a sample comprising the steps:20 a) providing a sample;b) contacting the sample with the monoclonal antibody or with the fragmentthereof according to claim 16 or 17; andc) detecting the presence of Porphyromonas gingivalis bacteria in thesample. 25 20. A kit for detecting the presence of Porphyromonas gingivalis bacteria in asample comprising (a) at least one antibody or fragments thereof as defined by claim 16 or 17.30 21. The kit according to claim 20, further comprising(b) at least one further antibody(c) a standard solution.GAR-P04580WO13 Application (final).docx98 ct5 The present invention relates to a synthetic saccharide of general formula (I) that is related to Porphyromonas gingivalis lipopolysaccharide specifically the O-antigen, aconjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and / or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for10 detection of antibodies against Porphyromonas gingivalis bacteria. Another aspect ofthe present invention is directed to a monoclonal antibody having specificity for a synthetic saccharide of general formula (I).GAR-P04580WO13 Application (final).docx99 Figures Figure 1GAR-P04580WO13 Application (final).docx

Images